Determinants of *de novo* B cell responses to drifted epitopes in post-vaccination

SARS-CoV-2 infections

Grace E. Quirk[1,*], Marta V. Schoenle[2,*,^], Kameron L. Peyton[2], Jennifer L. Uhrlaub[2],

Branden Lau[3], Jefferey L. Burgess[4], Katherine Ellingson[5], Shawn Beitel[4], James

Romine[4], Karen Lutrick[6], Ashley Fowlkes[7], Amadea Britton[7], Harmony L. Tyner[8], Alberto

J. Caban-Martinez[9], Allison Naleway[10], Manjusha Gaglani[11], Sarang Yoon[12], Laura

Edwards[13], Lauren Olsho[13], Michael Dake[14], Bonnie J. LaFleur[15], Janko Ž. Nikolich[,15,16],

Ryan Sprissler[3], Michael Worobey[1,15,#], and Deepta Bhattacharya[2,15,17,#]

[1] Department of Ecology and Evolutionary Biology, University of Arizona, Tucson, AZ,

USA

[2] Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ,

USA

[3] University of Arizona Genomics Core and the Arizona Research Labs, University of

Arizona Genetics Core, University of Arizona, Tucson, AZ, USA

[4] Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson,

Arizona, USA

[5] Department of Epidemiology and Biostatistics, Zuckerman College of Public Health,

University of Arizona, Tucson

[6] College of Medicine-Tucson, University of Arizona, Tucson, Arizona, USA

[7] National Center for Immunization and Respiratory Diseases, Centers for Disease

Control and Prevention, Atlanta, GA

[8] St. Luke's Regional Health Care System, Duluth, Minnesota, USA

[9] University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA

[10] Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA

[11] Baylor Scott & White Health and Texas A&M University College of Medicine, Temple,

Texas, USA

[12] Rocky Mountain Center for Occupational and Environmental Health, Department of

Family and Preventive Medicine, University of Utah Health, Salt Lake City, Utah, USA

[13] Abt Associates, Rockville, Maryland, USA

[14] Office of the Senior Vice-President for Health Sciences, University of Arizona,

Tucson, AZ, USA

[15] BIO5 Institute, University of Arizona, Tucson, AZ, USA

[16] University of Arizona Center on Aging, University of Arizona College of Medicine,

Tucson, AZ, USA

[17] Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA

*These authors contributed equally

#These authors contributed equally

^Current address: Department of Microbiology and Immunology, Cornell University,

Ithaca, NY

Address correspondence to: deeptab@arizona.edu

Summary:

Vaccine-induced immunity may impact subsequent *de novo* responses to drifted

epitopes in SARS-CoV-2 variants, but this has been difficult to quantify due to the

challenges in recruiting unvaccinated control groups whose first exposure to SARS-

CoV-2 is a primary infection. Through local, statewide, and national SARS-CoV-2

testing programs, we were able to recruit cohorts of individuals who had recovered from

either primary or post-vaccination infections by either the Delta or Omicron BA.1

variants. Regardless of variant, we observed greater Spike-specific and neutralizing

antibody responses in post-vaccination infections than in those who were infected

without prior vaccination. Through analysis of variant-specific memory B cells as

markers of *de novo* responses, we observed that Delta and Omicron BA.1 infections led

to a marked shift in immunodominance in which some drifted epitopes elicited minimal

responses, even in primary infections. Prior immunity through vaccination had a small

negative impact on these *de novo* responses, but this did not correlate with cross-

reactive memory B cells, arguing against competitive inhibition of naïve B cells. We

conclude that dampened *de novo* B cell responses against drifted epitopes are mostly a

function of altered immunodominance hierarchies that are apparent even in primary

infections, with a more modest contribution from pre-existing immunity, perhaps due to

accelerated antigen clearance.

Introduction:

Within a year of the discovery of SARS-CoV-2 as the etiological agent of COVID-19[1], highly effective vaccines were developed and administered. Leading this class were the monovalent mRNA vaccines BNT162b2 and mRNA-1273 encoding the ancestral Spike protein, both of which achieved ~95% efficacies in preventing symptomatic illness[2,3]. Other vaccine platforms also achieved high efficacies, especially against severe illness and hospitalization[4–8]. Since the initial results of these clinical trials, however, the protective capacity of these vaccines has declined[9–12]. This drop in vaccine effectiveness is due to both waning of antibodies and viral evolution and escape from vaccine-induced neutralizing antibodies, which are the best-known correlates of protection[13,14]. While the known genetic diversity of SARS-CoV-2 was quite modest through most of 2020[15], new variants with enhanced transmissibility and/or neutralizing antibody escape mutations have since emerged and sequentially swept to global dominance[12,16–24]. As of this writing, the dominant circulating variant is Omicron, which comprises sublineages that contain Spike protein mutations located within most known neutralizing antibody epitopes[25]. A key issue that will define both protection against infections and the strategy underlying updates to the vaccines is the extent to which pre-existing vaccine-induced immunity protects against heterologous challenges like Omicron.

B cell responses following mRNA COVID-19 vaccination are characterized by exceptionally long-lived germinal center reactions that persist for months while continuously improving the breadth and affinity of antibodies[26–29]. Cells exiting the germinal center carry affinity-enhancing mutations and can become long-lived antibody-

secreting plasma cells or memory B cells[30]. Depending on the subset of memory B cell,

re-exposures to antigen trigger differentiation to new plasma cells or germinal center

reactions[31–34]. After antigens from infection or vaccine antigens have been cleared,

long-lived plasma cells and memory B cells persist to maintain humoral immunity.

While these features protect against homologous SARS-CoV-2 infections, it is

more difficult to predict the nature of responses to subsequent heterologous infections

or vaccines. Due to their expanded pre-existing numbers and intrinsic signaling and

transcriptional differences relative to naive B cells, memory B cells rapidly mount

responses that are of greater magnitude than those of naïve primary responses[35–40] to

either initial infection or vaccination. Because of these properties, memory B cells that

react to epitopes conserved between the original and secondary challenges could

dominate the response to heterologous infections or vaccines[41–43]. If antigen and T cell

help are limiting, memory B cells might then outcompete naive B cells and new primary

antibody responses aimed at the new variant-specific epitopes. This phenomenon,

known as antigenic imprinting or "original antigenic sin"[44], can be beneficial if antibodies

against the conserved epitopes are protective. However, recall responses to

heterologous pathogens can potentially be neutral or even detrimental if antibodies

targeting these conserved epitopes are not protective and variant-specific primary

responses are competitively inhibited[45]. As an example of the phenomenon, pre-existing

common coronavirus-specific memory B cells compose a majority of the early response

to SARS-CoV-2, but primary responses to epitopes unique to SARS-CoV-2 are readily

observed later[26,46,47]. Whether common coronavirus immunity is helpful, harmful, or

neutral for *de novo* responses to SARS-CoV-2 is unknown.

In influenza infections, antigenic imprinting has been proposed to explain the

age-associated differential in morbidity and mortality based on influenza subtype

exposure history[48–51]. The various hemagglutinin (HA) subtypes of influenza A virus fall

into one or the other of two phylogenetically distinct HA "groups" (group 1 or group 2).

Individuals have the highest antibody titers against influenza strains encountered early

in life, and they experience enhanced protection against influenza strains that are within

the same HA group as their primary infection strain compared to heterosubtypic

infections from the group that is mismatched to their first childhood infection. Previous

work has shown that childhood exposure to H1N1 (group 1 hemagglutinin (HA)) affords

protection against other group 1 HAs, such as H5N1. The same is true for individuals

with group 2 HAs, whereby childhood H3N2 infection affords protection against H7N9.

Conversely, individuals with group 1 imprinting experience an increase in mortality when

faced with a group 2 influenza virus infection, such as that observed for H7N9

infections[48,51].

Though pre-existing immunity can certainly impact primary responses to

heterologous antigens, other mechanisms can also limit antibody responses to drifted

epitopes. Epitopes that were previously immunodominant for antibody responses do not

necessarily remain so once mutated, irrespective of prior immunity[52]. There are several

possible mechanistic reasons why not all epitopes are equal for antibody responses.

Factors such as naïve antigen-specific B cell precursor frequency and avidity vary

greatly across epitopes, which in turn correlate with their relative contribution to the

subsequent response[53–57]. Some epitopes can also be biophysically challenging for

antibody binding, such as those sterically blocked by glycan shields or appearing as

non-complex 'smooth' surfaces to B cells[58,59]. Further, epitopes that mimic self-antigens

also elicit poor responses due to tolerance mechanisms that remove or hamper B cells

from the repertoire that could otherwise respond[60–63]. Finally, V gene usage during

V(D)J recombination that gives rise to B cell receptors is uneven, as some segments

are more heavily utilized than others[64,65]. In turn, this can create 'holes' in the repertoire,

rendering some epitopes poorly immunogenic[66]. As SARS-CoV-2 variants of concern

accumulate mutations in antigenic regions, immunodominance might change in ways

that limit responses to drifted epitopes, with or without prior immunity. Thus, it has

remained difficult to examine the degree to which infrequent *de novo* variant-specific

responses in post-vaccination infections and heterologous boosters are due to changes

in immunodominance, antigenic imprinting, or some combination of both[67–75].

Antigenic imprinting has remained nearly impossible to quantify directly and

instead has predominantly relied on historical epidemiological data to make inferences

about biological mechanisms that produce the documented patterns[48,76,77]. The COVID-

19 pandemic presents a unique opportunity to address these questions: it has

encompassed adults with known infection histories and monovalent vaccines that

induce well characterized B cell responses[78–81] and the emergence of antigenically

distinct viral variants[25,82]. Yet, as immunological histories become more complex and

with very few immunologically naïve adults remaining[83,84], the Omicron BA.1 (BA.1, for

short) wave likely represented the final opportunity to recruit robust cohorts of

individuals that meet the key experimental and control criteria. Through voluntary saline-

gargle PCR testing of University of Arizona students, staff, and faculty as part of COVID

mitigation efforts on campus from August 2020 to July 2023; serological testing at 17

University of Arizona-managed sites across the state of Arizona; and two CDC-funded

cohorts of essential workers, Arizona Healthcare, Emergency Response, and Other

Essential Workers Surveillance (AZ HEROES)[85] and Research on Epidemiology of

SARS-CoV-2 in Essential Response Personnel (RECOVER)[86], we recruited

unvaccinated individuals who had recovered from primary Delta (B.1.617.2 or

B.1.617.2-like) or BA.1 (B.1.1.529 or B.1.1.529-like) infections. These cohorts allowed

us to characterize the immunodominance hierarchies for both Delta and BA.1 variants

and directly compare the specificity of antibody responses in unvaccinated individuals

infected by the antigenically drifted viral variants to those generated by post-vaccination

infection by Delta or BA.1. In doing so, we were able to quantify the impact of antigenic

imprinting on *de novo* responses to drifted epitopes.

Results:

From our voluntary on-campus testing program at the University of Arizona, we recruited 37 participants who had tested positive for SARS-CoV-2 infections between July 1, 2021 and December 1, 2021 despite completion of the primary vaccine series of monovalent BNT162b2 or mRNA-1273 prior to infection (described in detail in Methods section). We also recruited 12 individuals who tested positive during this period but had not received any COVID-19 vaccines. Symptoms reported by participants following infections were similar between primary and post-vaccination infections; none required hospitalization. A slightly larger portion of post-vaccination infections were asymptomatic relative to primary infections (**Figure S1A**), and in general, the duration of symptoms was significantly shorter in this group relative to those who were unvaccinated at the time of infection (**Figure S1B**). All recruited individuals who tested positive by RT-qPCR and had sufficient sequence coverage to assign a lineage had sequences confirmed to be Delta (**Figure S2A**). During this period, the Delta variant represented 100% of PCR+ samples on campus that could be assigned a PANGO-lineage[87], as determined through viral sequencing of all remnant samples below a Ct value of 35 (**Figure S2B**). We also selected 71 serum samples as part of our statewide antibody testing initiative[88] from vaccinated participants who had no self-reported prior SARS-CoV-2 infections. This cohort was chosen based on matching for age, sex, and time post-vaccination with our post-vaccination infection group. Characteristics of the cohorts are listed in **Table 1**.

Participants provided blood samples at an average of 75 days (IQR for primary and post-vaccination infections = 45.8 days, 97.3 days; **Table 1**) after testing positive for

SARS-CoV-2 infections and at an average of nine months (IQR for vaccinated only and

post-vaccination infections = 56 days, 317 days; **Table 1**) after their last vaccine dose.

Using plasma from these samples, we first performed live virus neutralization assays on

both an early-pandemic virus representative, (WA-1, from January 2020) or on the

antigenically drifted Delta variant. Against both WA-1 and Delta, post-vaccination Delta

infections led to significantly higher titers of neutralizing antibodies than both primary

infections and vaccinated only controls (**Figure 1A**), indicating a robust recall response.

Elevated neutralizing antibody titers in post-vaccination Delta infections could

arise from both memory B cell responses to conserved neutralizing epitopes and

primary responses against new variant-specific epitopes. To begin to determine the

relative specificities of antibodies following Delta infections, we performed ELISAs to

measure the magnitude of the antibody response against Wuhan/Hu1/2019 (hereafter

WuHu1) and Delta Spike antigens. WuHu1 was sampled in December 2019 and is the

SARS-CoV-2 reference sequence; its Spike amino acid sequence is identical to that of

WA-1. We first measured antibodies that bound the receptor binding domain (RBD), as

most neutralizing antibodies target this region[89,90]. Post-vaccination Delta infections led

to elevated RBD-binding antibody titers, both against WuHu1 and Delta, relative to

vaccination only and primary Delta infection controls (**Figure 1B**), again confirming a

robust recall response. As expected, vaccination-only controls showed slightly elevated

titers of WuHu1 RBD-binding antibodies relative to Delta RBD antibodies (**Figure 1B,**

right panel). Reciprocally, primary Delta infections led to a skewing towards Delta

RBD-binding antibodies (**Figure 1B, right panel**). Post-vaccination-Delta infections led

to an even ratio of WuHu1:Delta RBD-binding antibodies (**Figure 1B, right panel**),

similar to prior studies[91]. Aside from the RBD, neutralizing antibodies can also bind

other regions of the S1 domain of Spike[92–94]. As with RBD, post-vaccination Delta

infections led to an even ratio of antibodies that bound WuHu1 and Delta S1 relative to

vaccination alone or primary Delta infections (**Figure S3**).

To more directly assess antibody specificities with single cell resolution in post-

vaccination Delta infections, memory B cells using WuHu1 S1 and Delta S1 antigen

tetramers were quantified by flow cytometry. We focused our analysis on the isotype-

switched CD27+ subset (**Figure 2A and Figure S4**), since few Spike-specific cells are

observed in other memory B cell subsets[95]. Memory B cells that bound Delta S1 only

were observed in both primary infections and in post-vaccination Delta infections,

suggesting that in both cases, *de novo* responses aimed at variant-unique epitopes

were mounted (**Figure 2A-B**). However, the proportions of these cells in PBMCs were

slightly reduced in post-vaccination Delta infections relative to primary Delta infections

(**Figure 2B**). Reciprocally, cross-reactive memory B cells that bound both WuHu1 S1

and Delta S1 were elevated in post-vaccination Delta infections relative to primary Delta

infections (**Figure 2B**), consistent with a robust recall response and antigenic imprinting,

though for a subset of individuals this appears to be more modest. In both primary and

post-vaccination Delta infections, memory B cells that bound Delta S1 uniquely were

rare relative to cross-reactive cells that bound both WuHu1 and Delta S1 (**Figures 2A-**

B). Although these data suggest that pre-existing immunity limits new primary

responses, cross-reactive and Delta-specific memory B cells were positively correlated

in post-vaccination Delta infections (**Figure 2C**), arguing against a mechanism of

competitive inhibition between these two cellular compartments.

The RBD of Delta contains two non-synonymous point mutations that deviate

from the vaccine sequence: T478K and L452R. The L452R mutation in particular leads

to neutralizing antibody escape[90,96–98]. To estimate the epitope preferences of serum

antibodies further, we produced a Delta RBD protein in which R452 was reverted to

L452. Vaccination led to a response that was skewed toward the L452-containing RBD

(**Figure 3A,** compare to **Figure 1B, middle panel**), confirming the strong antibody bias

and immunodominance of this epitope reported previously[99]. Yet reciprocal skewing to

R452-containing RBD was not observed in primary Delta infections, suggesting that a

new immunogenic epitope is not created by this mutation (**Figure 3A**). Post-vaccination

Delta infections led to a relatively even ratio of antibodies that bound Delta-L452 to

those that reacted to Delta-R452 (**Figure 3A**), perhaps due to boosted levels of

antibodies that bound other conserved sites on RBD and the T478K epitope. We also

produced chimeric WuHu1 S1 proteins in which the Delta N-terminal domain (NTD)

supersite mutations (T19R, G142D, E156-, F157-, R158G) were introduced onto a

WuHu1 background[92–94]. Vaccination only controls showed a relatively even distribution

of antibodies that bound WuHu1 S1 and Delta NTD-WuHu1 S1 (**Figure 3B** compare to

Figure S3, left panel). Primary Delta infections, however, were subtly but significantly

skewed towards the Delta NTD (**Figure 3B**). Together, these data demonstrate a

shifting of immunodominance profiles, even in the absence of prior SARS-CoV-2

immunity.

To more precisely measure clonal shifts in antibody specificities and

immunodominance than can be achieved by serological assays, we performed LIBRA-

seq using PBMC samples from primary and post-vaccination Delta infections[100].

Streptavidin-phycoerythrin (PE) tetramers were constructed using WuHu1 S1, Delta S1,

Delta RBD, Delta RBD-L452, and Delta NTD-WuHu1-S1, as described in **Figures 1, 3**

and **S3**, each carrying unique oligonucleotide barcodes. PE-binding memory cells were

then enriched and subjected to scRNA/V(D)J-seq. Consistent with our serological data

(**Figure 3A-B**), we observed few memory B cells that bound Delta RBD- and NTD-

specific epitopes (**Figure 3C**) in primary Delta infections and post-vaccination Delta

infections (**Figure S5A**). A clear preference for Delta-unique epitopes in the NTD

relative to the RBD was observed within individuals that had experienced a primary

Delta infection (**Figure 3D**). Within each group, we did not observe any clear differences

in epitope-dependence of somatic mutation frequencies in memory B cells (**Figure**

S5B). We did, however, observe a greater frequency of somatic mutations in Spike-

specific memory B cells in the post-vaccination Delta infection cohort relative to primary

Delta infections (**Figure S5C**). Together, these data suggest a marked shift in antibody

specificities in primary Delta variant infections relative to WuHu1 Spike. This explains in

part why responses to at least some drifted epitopes are not observed, irrespective of

prior vaccination.

During the course of this work, the heavily mutated Omicron (BA.1) variant

rapidly overtook Delta and swept to global dominance. To define post-vaccination BA.1

responses, we recruited individuals from our voluntary on-campus testing program who

had tested positive for SARS-CoV-2 between January 1 and March 31, 2022, with the

expectation that primary responses would be robust against this more antigenically

distant variant[101]. All individuals for this study who tested positive by PCR had

sequences confirmed to be BA.1 (**Figure S2A**). Individuals with a SARS-CoV-2

infection caused by a Delta variant or other Omicron sublineages were excluded from

the study. Viral genome sequencing of all remnant PCR+ samples on campus during

this period below a Ct value of 35 demonstrated that 93.7% of samples that could be

assigned a PANGO-lineage[87] were caused by the BA.1 sublineage of Omicron (**Figure**

S2B). To obtain controls for this cohort, some of whom had received 3 doses of mRNA

vaccines, we also recruited a new group of vaccinated individuals who had never tested

positive in our voluntary university testing system and reported no known prior SARS-

CoV-2 infections. After testing plasma for nucleocapsid antibodies as a marker of prior

infection, samples from 5 individuals with titers well above the mean values seen in

verified infections were excluded from further consideration (**Figure S6**). Relative to

both primary and post-vaccination Delta infections, post-vaccination BA.1 infections

generally led to fewer symptoms such as wet cough (**Figure S1A**) and shorter duration

of symptoms (**Figure S1B**).

We were unable to recruit any unvaccinated individuals on campus who had

experienced BA.1 infections. However, we were able to obtain serum and, for a subset,

PBMC samples from a separate study from the Centers for Disease Control and

Prevention HEROES and RECOVER projects[85], in which 53 individuals met these

criteria (**Table 1**). Neutralizing antibody titers were skewed towards WA-1 in individuals

who had been vaccinated but not infected (**Figure 4A**). Post-vaccination BA.1 infections

led to significantly higher neutralizing antibody titers against BA.1 compared to both

vaccinated controls who had not been infected and primary infections (**Figure 4A**),

consistent with a memory B cell recall response.

We next examined binding antibody titers against WuHu1 or BA.1 RBD. Post-

vaccination BA.1 infections led to increased levels of RBD-binding antibodies, both for

WuHu1 and BA.1, relative to the vaccinated only control cohort and primary BA.1

infections (**Figure 4B, left and middle panels**). Vaccination alone led to greater RBD

titers against BA.1 than did primary BA.1 infections, despite the many mismatches in

sequence (**Figure 4B, middle panel**). As expected, antibodies from vaccinated only

individuals were skewed towards WuHu1 relative to BA.1 RBD (**Figure 4B, right**

panel). Of the few antibodies induced by primary BA.1 infections, we observed a

skewing of specificities towards BA.1 RBD (**Figure 4B, right panel**). Ratios of WuHu1

and BA.1 RBD-binding antibodies in post-vaccination BA.1 infections more closely

resembled vaccinated controls than primary BA.1 infections (**Figure 4B, right panel**).

To further evaluate the specificities of antibody responses in post-vaccination

BA.1 infections, we again used antigen tetramers to identify RBD-specific memory B

cells (**Figures S7 and 5A**). As expected, primary BA.1 infections generated a lower

frequency of WuHu1 RBD-specific memory B cells compared to vaccinated controls

(**Figure 5B, left panel**). Unexpectedly, BA.1-specific RBD memory B cells were not

consistently detectable above background in any experimental group, even primary

BA.1 infections (**Figure 5B, middle panel**). These data seem to differ from the modest

skewing of the serological response seen above in primary BA.1 infections (**Figure 4B,**

right panel), but can potentially be explained by low overall responses and prior studies

that observed only partial overlap between memory B and antibody-secreting plasma

cell specificities and repertoires[43,102,103]. Instead, most RBD-specific memory B cells

from all cohorts were cross-reactive against WuHu1 and BA.1 RBD (**Figure 5A, 5B,**

right panel). Primary BA.1 infections produced numerically fewer cross-reactive RBD

memory B cells than did post-vaccination BA.1 infections (**Figure 5B, right panel**).

Given that the overall antibody and memory B cell response to BA.1 RBD was

quite modest (**Figures 4B, 5A-B**), we employed tetramers of full-length Spike trimers of

WuHu1 and BA.1 Spike to capture a greater breadth of memory B cell specificities than

could be observed with RBD tetramers (**Figures 5C**). WuHu1-specific memory B cells

were observed in vaccinated controls and post-vaccination BA.1 infections, but not after

primary BA.1 infections (**Figures 5D, left panel**). We again failed to consistently

observe BA.1-specific memory B cells in any of the groups, including primary BA.1

infections, though a subset of post-vaccination BA.1 infections did appear to generate

such cells well above background levels (**Figure 5D, middle panel**). As with RBD,

cross-reactive Spike-specific memory cells were significantly elevated in post-

vaccination BA.1 infections relative to primary BA.1 infections, but not relative to

vaccinated only controls (**Figure 5D, right panel**). Cross-reactive memory B cells

composed by far the largest portion of SARS-CoV-2 specific responses within all

experimental groups (**Figure S8**).

For a subset of primary BA.1 and post-vaccination BA.1 cohorts, we obtained

samples which enabled us to quantify WuHu1, BA.1, and cross-reactive Spike- and

RBD- specific memory B cell frequencies before and after BA.1 infection. Irrespective of

vaccination status, memory B cells that were either WuHu1- or BA.1-RBD-specific

increased in frequency for only a subset of individuals after BA.1 infection (**Figure 6A,**

left and middle panels). However, cross-reactive RBD memory B cells consistently

and significantly increased after both primary and post-vaccination BA.1 infections

(**Figure 6A, right panel**). The frequency of cross-reactive Spike memory B cells also

significantly increased after primary BA.1 infections (**Figures 6B, right panel**).

349   To infer potential mechanisms of antigenic imprinting from these samples, we

first correlated pre-infection cross-reactive Spike-specific memory B cells and post-

infection BA.1 Spike-specific memory B cells. A negative correlation could indicate

detrimental imprinting, whereby pre-existing memory B cells outcompete naïve B cells

and inhibit the generation of variant-specific responses. Instead, we observed a slight

positive but non-statistically significant correlation between pre-infection cross-reactive

Spike-specific memory B cells and post-infection BA.1 Spike-specific memory B cells

(**Figure 7A**). Similarly, we observed a non-significant positive correlation between post-

infection cross-reactive Spike-specific memory B cells and post-infection BA.1 Spike-

specific memory B cells (**Figure 7B**).

359   Given that these data do not support a mechanism of competitive inhibition of

naïve B cells by cross-reactive memory B cells, we explored other mechanisms by

which *de novo* responses to drifted epitopes are indirectly suppressed, such as

accelerated viral clearance by neutralizing antibodies and/or T cells. We found a

negative, but non-statistically significant correlation of *de novo* responses with pre-

infection BA.1 neutralizing antibody titers (**Figure 7C**). Similarly, we observed a small

and non-significant negative correlation with pre-infection BA.1 Spike-specific T cell

numbers and post-infection BA.1 Spike memory B cells (**Figure 7D**). The small sample

sizes and variable times of blood sampling prior to infection preclude us from making

definitive conclusions about mechanisms driving antigenic imprinting. Nonetheless, the

data suggest that neutralizing antibody and/or memory T cell-mediated viral clearance

may indirectly underlie suppression of responses to drifted epitopes. This overall impact

is quite small relative to the marked changes in antibody immunodominance observed

in even primary BA.1 variant infections, irrespective of prior immunity.

Discussion:

Antigenic imprinting is neither inherently beneficial nor detrimental; rather the impact of prior immunity is context-dependent[45]. For example, pre-existing serum antibodies can improve and focus *de novo* responses upon reinfection to only mutated novel epitopes through epitope masking[104–106]. Similarly, *de novo* responses to drifted epitopes can be improved by pre-existing CD4+ memory T cells in what is classically known as the hapten-carrier effect[107]. Alternatively, high affinity memory B cells can competitively inhibit naïve B cells by consuming limited amounts of antigen and T cell help, leading to a suppression of *de novo* antibody responses[108]. If these memory B cells target non-protective epitopes, this could in theory leave one worse off than if there were no prior immunity whatsoever[44,109]. Finally, pre-existing immunity could indirectly suppress new antibody responses to drifted epitopes simply by clearing away virus and antigen before naïve B cells can robustly participate.

Though neutralizing antibody titers were robust following post-vaccination infections, our results demonstrated a small negative impact of prior immunity on *de novo* responses to drifted epitopes. Yet we found no evidence to support a mechanism of competitive inhibition by cross-reactive memory B cells. Though not definitive, our data instead hint at a role for pre-infection neutralizing antibodies and memory T cells, suggesting that antigen clearance is the main mechanism by which *de novo* B cell responses are indirectly suppressed by prior immunity. Indeed, pre-existing neutralizing antibodies likely accelerate viral clearance[110,111], and viral and vaccine antigens can potentially also be cleared by T cells or non-neutralizing antibodies via Fc effector functions[112–114]. Animal studies offer an attractive way to further test mechanisms of

antigenic imprinting on heterologous vaccine and viral infection responses. For

example, genetic tracking studies were used to show robust *de novo* responses to

Omicron boosters in mice previously vaccinated against the ancestral strain. Yet this

required two booster doses, and a small negative impact of prior immunity was

observed in inverse proportion to the antigenic distance between the two

immunizations[101]. Similar results have been reported in other mouse studies[115]. These

systems can thus potentially be used to manipulate specific immune parameters and

measure their contributions to antigenic imprinting in ways that are not possible in

human studies, especially since few immunologically naïve adults remain to serve as

controls.

Immunodominance hierarchies can also determine which epitopes are available

to be targeted by antibodies, irrespective of prior immunity. Prior studies, confirmed in

our experiments, showed that a large portion of COVID-19 vaccine-induced antibodies

are aimed at the L452 class 3 epitope[116]. Yet in the post-vaccination Delta cohort, we

observed few antibodies directed at the epitope containing the L452R mutation. Under

the assumption that one immunodominant epitope was being mutated to another, one

might have concluded that the absence of R452-specific antibodies could be explained

by antigenic imprinting. Yet by including a primary infection cohort, we observed that the

Delta variant intrinsically did not elicit detectable antibody responses against the R452

epitope, even with no prior SARS-CoV-2 exposures, consistent with an independent

study[52]. We can instead conclude that Delta shifts antibody immunodominance

hierarchies to instead focus more on epitopes located in the NTD. These types of shifts

in immunodominance preempt any considerations of the impact of antigenic imprinting.

The basis and mechanisms of these shifts for SARS-CoV-2 clearly needs more

investigation to determine whether and how best to overcome them.

This study spanned a period from the Delta wave through the more antigenically

distinct BA.1 Omicron wave. A central expectation of antigenic imprinting is that the

extent to which prior immunity interferes with *de novo* responses should decrease as

antigenic distance increases[101]. We used the Delta and BA.1 variants to test this

expectation in SARS-CoV-2 and to understand the impacts of antigenic distance on

antigenic imprinting. Despite our prediction, we observe even less of a variant specific

response in post-vaccination BA.1 infections compared to post-vaccination Delta

infections. Much of this can be explained by shifts in immunodominance in which even

primary BA.1 infections elicited few memory B cell responses to drifted epitopes. Yet

longitudinal sampling during BA.1 infections has also shown that viral titers do not reach

the peak levels observed in Delta infections[117], suggesting that immune responses to

drifted epitopes occur in proportion to need and antigen availability.

Disclosures: The findings and conclusions in this report are those of the authors and

do not necessarily represent the official position of the Centers for Disease Control and

Prevention.

Acknowledgements: This work was supported by NIH grants R01AI099108 and

R01AI129945 (D.B.) and a research grant from the Arizona Board of Regents (M.W.

and D.B). This project has been funded in part with Federal funds from the National

Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of

Health and Human Services, under Contract No. 75N93021C00015 (M.W.) The

HEROES-RECOVER cohort is supported by the National Center for Immunization and

Respiratory Diseases and the Centers for Disease Control and Prevention (contracts

75D30120R68013 to Marshfield Clinic Research Institute, 75D30120C08379 to the

University of Arizona, and 75D30120C08150 to Abt Associates).

Declaration of Interests: Sana Biotechnology has licensed intellectual property of D.B.

and Washington University in St. Louis. Gilead Sciences has licensed intellectual

property of D.B. and Stanford University. Clade Therapeutics has licensed intellectual

property of D.B. and University of Arizona. D.B. is a co-founder of Clade Therapeutics.

D.B. served on an advisory panel for GlaxoSmithKline. B.J.L. has a financial interest in

Cofactor Genomics, Inc. and Iron Horse Dx. Geneticure Inc. has licensed intellectual

property of R.S. and R.S is a co-founder of Geneticure Inc. M.W. has received

consulting fees from GLG on SARS-CoV-2 and the COVID-19 pandemic.

Methods:

Participant selection

All human studies conducted at The University of Arizona were approved by the

Institutional Review Board for the Human Subjects Protection Program[†]. Individuals who

had participated in the voluntary on-campus saline gargle testing program and had

either never tested positive or had tested positive during the Delta or BA.1 waves were

contacted by email by the program administrators (not the authors on this study) about

willingness to participate in this research study. Participants were provided a link to an

eligibility questionnaire and, once eligibility (no immunosuppressive therapy in the last 5

years and HIV negative) was confirmed, additional demographic questions and a link to

schedule an appointment for blood draws. Written consent was obtained through an

electronic form. All blood draws were performed at the Clinical and Translational

Sciences Center at The University of Arizona. Additional primary and post-vaccination

BA.1 infection samples were acquired from the CDC HEROES-RECOVERS[††] cohort[85].

This study was reviewed by CDC and approved by the institutional review boards at

participating sites or under a reliance agreement with Abt Associates institutional review

board and was conducted consistent with applicable federal law and CDC policy under

45 C.F.R. part 46, 21 C.F.R. part 56, 42 U.S.C. Sect. 241(d), 5 U.S.C. Sect. 552a, 44

U.S.C. Sect. 3501 et seq. Methods for the HEROES-RECOVER Cohorts have

been published previously[85,86]. In summary, cohorts consisted of health care

personnel, first responders, and other essential and frontline workers in eight

U.S. locations across six states. Participants collected weekly nasal swabs which

were tested for SARS-CoV-2 viral material by RT-qPCR and additional swabs

were collected and screened upon the onset of any COVID-19–like illness

symptoms. In addition, blood draws were collected at enrollment, then

approximately every 3 months and after immune modifying events such as

vaccination or infection. Vaccination was documented by self-report and verified

by vaccine cards or electronic medical records or state immunization registries.

HEROES-RECOVER participants were selected based on testing positive for SARS-

CoV-2 during Delta or BA.1 waves and having completed a blood draw after infection.

Saline Gargle PCR testing for SARS-CoV-2

As part of Test All, Test Smart, the University of Arizona's voluntary campus-wide

testing program, University staff, faculty and students had access to SARS-CoV-2 rRT-

PCR tests from August 2020 – July 2023. At testing and collection sites throughout

campus, individuals were given 5 mL of 0.9 % sterile saline (AddiPak 5 mL sterile saline

single use tubes, Teleflex, LLC) and guided to complete three rounds of a 5-second

swish followed by 10 seconds of gargling (adapted from Goldfarb et al.[118]). Samples

were deposited into collection tubes and then screened for SARS-CoV-2 by rRT-PCR.

PBMC and plasma preparation

Twenty milliliters of blood was collected by venipuncture in heparinized Vacutainer

tubes (BD). For PBMCs, 15ml of Ficoll-Paque PLUS (Thermo Fisher Scientific) was

added to 50-ml Leucosep tubes (Greiner) and spun for 1min at 1,000g to transfer the

density gradient below the filter. Twenty milliliters of blood from the heparinized tubes

was then poured into the top of the Leucosep tube and spun at 1,000g for 10min at

room temperature with the brake off. The top plasma layer was carefully collected and

frozen at −20 °C, and the remaining supernatant containing PBMCs above the filter was

poured into a new 50-ml conical tube containing 10mL of PBS and spun at 250g for

10min. Cell pellets were resuspended in RPMI media containing 10% FCS and counted

on a Vi-Cell XR (Beckman Coulter). Cells were diluted to a concentration of 2×10^7

cells per mL in RPMI media containing 10% FCS. An equal volume of 80% FCS + 20%

dimethyl sulfoxide was added dropwise and inverted once to mix. Suspensions were

distributed at 1ml per cryovial and frozen overnight at −80 °C in Mr. Frosty freezing

chambers (Nalgene). Vials were then transferred to storage in liquid nitrogen.

ELISA and quantification of antibody titers

Serological assays were performed as previously described[88]. WuHu1 RBD (cat. no.

SPD-C52H3), WuHu1 S1subdomain of the SARS-CoV-2 S glycoprotein (cat. no. S1N-

C52H3), WuHu1 Spike (cat. no. SPN-C52H9), Delta RBD (cat. no. SPD-C52Hh), Delta

S1 subdomain (cat. no. S1N-C52Hu), Omicron (BA.1) RBD (cat. no. SPD-C522e),

Omicron (BA.1) Spike (cat. no. SPN-C52Hz) and Nucleocapsid (cat. no. NUN-C5227)

were purchased from Acro Biosystems. Chimeric proteins (Delta RBD-L452 and Delta

NTD-WuHu1 S1) were custom synthesized by GenScript. To obtain titers and single-

dilution OD450 values, antigens were immobilized on high-adsorbency 384-well plates

at 5 ng mL^{-1}. Plates were blocked with 1% non-fat dehydrated milk extract (Santa Cruz

Biotechnology, sc-2325) in sterile PBS (Thermo Fisher Scientific HyClone PBS,

SH2035) for 1 h, washed with PBS containing 0.05% Tween-20 and overlaid for 60 min

with either a single 1:60 dilution or five serial 1:3 dilutions beginning at a 1:60 dilution of

serum. Plates were then washed and incubated for 1 h in 1% PBS and milk containing

anti-human Pan-Ig HRP-conjugated antibody (Jackson ImmunoResearch, 109-035-064)

at a concentration of 1:2,000 for 1 h. Plates were washed with PBS-Tween solution

followed by PBS wash. To develop, plates were incubated in tetramethylbenzidine

(Fisher Scientific) before quenching with 2 N H_2SO_4. Plates were read for 450-nm

absorbance on CLARIOstar Plus from BMG Labtech. All samples were also read at

630 nm to detect any incomplete quenching. Any samples above background 630-nm

values were re-run. Area under the curve (AUC) values were calculated in GraphPad

Prism (v9).

Virus neutralization assays

All live virus assays were performed at Biosafety Level 3 and were approved by the

University of Arizona Institutional Biosafety Committee. SARS-CoV-2, isolate USA-

WA1/2020, was deposited by Dr Natalie J. Thornburg at the Centers for Disease

Control and Prevention and obtained from the World Reference Center for Emerging

Viruses and Arboviruses. Stocks of WA1/2020 SARS-CoV-2 were generated as a single

passage from received stock vial on mycoplasma-negative Vero cells (ATCC CCL-81).

B.1.617.2 (Delta) was received from WRCEVA, strain designation GNL-1205. B.1.1.529

(Omicron) originated from a nasopharyngeal swab collected at the University of Arizona.

It was passaged once on Calu-3 cells and then once on Vero cells to generate a master

stock. Viral PANGO-lineage, BA.1.1[87], was confirmed by Illumina sequencing

(EPI_ISL_17886211) of the master stock.

Supernatant and cell lysate were combined, subjected to a single freeze–thaw

and then centrifuged at 1,800g for 10min to remove cell debris. For PRNTs for SARS-

CoV-2, Vero cells (ATCC, CCL-81) were plated in 96-well tissue culture plates and

grown overnight. Vero cells were confirmed by PCR to be free of mycoplasma using the

Universal Mycoplasma Detection Kit (ATCC). Serial dilutions of serum samples were

performed in duplicate and incubated with 100 plaque-forming units of SARS-CoV-2 for

1h at 37 °C. Plasma/serum dilutions plus virus were transferred to the cell plates and

incubated for 2h at 37 °C in 5% CO2 and then overlaid with 1% methylcellulose. After

72h, plates were fixed with 10% neutral buffered formalin for 30min and stained with 1%

crystal violet. Plaques were imaged using an ImmunoSpot Versa plate reader. The most

dilute serum concentration that led to ten or fewer plaques was designated as the

PRNT90 titer. Input PFU for each experiment was confirmed by plaque assay.

Flow cytometry

One milliliter of pre-warmed FBS was added to a frozen cryovial of 10^7 PBMCs, which

was rapidly thawed in a 37℃ water bath. Samples were poured into 15 mL conical tubes

containing 5 mL of pre-warmed RPMI with 5% FBS and 1% anti/anti. Tubes were spun

at 250g for 5 min at room temperature.

Delta

Supernatants were removed and cell pellets were resuspended in 200 µL of staining

buffer containing 1 µL each of anti-CD38-APC (BioLegend, clone HIT2), anti-CD13-PE-

Cy7 (BioLegend, clone WM15), anti-CD21-PE-Dazzle (BioLegend, clone Bu32), anti-

CD19-APC-efluor-780 (Invitrogen, clone HIB19), anti-IgD-PerCP-Cy5.5 (Biolegend,

clone IA6-2), anti-IgM-FITC (Biolegend, clone MHM-88), anti-CD27-BV510 (Biolegend,

clone M-T271), anti-CD11c-Alexa700 (BioLegend, clone Bu15). Staining buffer also

contained Delta-S1-PE and S1-BV421 tetramers.

BA.1

Supernatants were removed and cell pellets were resuspended in 200 μL of staining

buffer containing 1 μL each of anti-CD38-BV421 (BioLegend, clone HB-7), anti-CD13-

PE-Dazzle 594 (BioLegend, clone WM15), anti-CD21-PerCP Cy 5.5 (BioLegend, clone

Bu32), anti-CD19-APC-efluor-780 (Invitrogen, clone HIB19), anti-IgD-BV510

(Biolegend, clone 11-26c.2a), anti-IgM-FITC (Biolegend, clone MHM-88), anti-CD27-PE

Cy 7 (Biolegend, clone M-T271), anti-CD11c-Alexa700 (BioLegend, clone Bu15). Cells

were stained with live-dead marker, Zombie Yellow (BioLegend) according to

manufacturer's recommendations. Staining buffer also contained BA.1-Spike-PE and

Spike-Alexa Fluor 647 tetramers.

Antibodies were validated by the manufacturer on human PBMCs. Tetramer reagents

were assembled by mixing 100μg ml^{-1} of C-terminal AviTagged S1, Delta S1, WuHu1

Spike, or BA.1 Spike (ACROBiosystems) with 100μg ml^{-1} of streptavidin-PE(BioLegend),

streptavidin-BV421 (BioLegend), or streptavidin-Alexa Fluor 647 (BioLegend),

respectively, at a 6:1 molar ratio for S1 or 4:1 molar ratio for Spike, in which ⅕ of the

final volume of streptavidin was added every 10 min. S1 and Spike tetramers were

validated by staining Lenti-X 293T cells(Takara Bio) as a negative control or 293T-

hACE2-expressing cells (BEI Resources, NR-52511) as a positive control. Lenti-X 293T

cells were confirmed to be free of mycoplasma; 293T-hACE2 cells were maintained in

media containing 1% pen/strep to minimize chances of contamination. PBMC samples

were stained for at least 20 minutes, washed and filtered through 70-μm nylon mesh.

Data were analyzed on either a BD LSR2 (tetramer validation only), a Fortessa

cytometer (Delta), or BD Cytek Aurora (BA.1). Data were analyzed using FlowJo

software.

Flow cytometry and Fluorescence Activated Cell Sorting

One milliliter of pre-warmed FBS was added to a frozen cryovial of PBMCs and thawed

by pipetting. Samples were added to 15 mL conical tubes containing 10 mL of pre-

warmed RPMI with 20% FBS and 1% anti/anti. Tubes were spun at 1200 RPM for 5

minutes at room temperature. Supernatants were removed and cell pellets were

resuspended in 200 μL of staining buffer contained 1 μL each of anti-CD19-

BV421(Biolegend, clone HIB19), anti-CD27-FITC(Biolegend, clone O323), anti-CD13-

PE-Cy-7(Biolegend, clone WM15), anti-IgD-APC-Cy-7(Biolegend, clone IA6-2). Staining

buffer also contained either 5 or 2 LIBRA-Seq tetramers: S1-PE(Biolegend, TotalSeq-

C0951_PE), Delta S1-PE(Biolegend, TotalSeq-C0952_PE), Delta NTD/S1-

PE(Biolegend, TotalSeq-C0953_PE), Delta RBD/L452(Biolegend, TotalSeq-

C0954_PE), and Delta RBD-PE(Biolegend, TotalSeq-C0955_PE). Biotinylated tetramer

reagents were assembled by mixing 100μg ml^{-1} of C-terminal AviTagged S1

(ACROBiosystems), Delta S1 (ACROBiosystems), Delta NTD/S1 (GenScript), Delta

RBD/L452 (Genscript), or Delta RBD (ACROBiosystems) with 100μg ml^{-1} of

streptavidin-TotalSeq-C-PE (BioLegend) at a 6:1 molar ratio in which ⅕ of the final

volume of streptavadin was added every 10 min. Tetramers were validated by staining

Lenti-X 293T cells(Takara Bio) as a negative control or 293T-hACE2-expressing cells

(BEI Resources, NR-52511) as a positive control. Lenti-X 293T cells were confirmed to

be free of mycoplasma; 293T-hACE2 cells were maintained in media containing 1%

pen/strep to minimize chances of contamination. Additionally, TotalSeq-C anti-human

Hashtag antibodies (Biolegend, TotalSeq™-C0251-10) were added to individual

samples and pooled after staining and washing. PBMCs were stained in the dark for 30

minutes at 4˚C, washed, pooled and filtered through a 35 µm strainer (Fisher Scientific).

SARS-CoV-2 specific memory B cells (CD19+IgD-IgM-CD27+) as well as non-antigen

specific memory B cells were sorted using a FACSAria II.

Single-cell RNA sequencing and analysis

Cells were prepared and processed according to the 10X Genomics Single Cell 5' Dual

Index protocol with Feature Barcoding Technology for Cell Surface Protein and Immune

Receptor Mapping kit (10X Genomics). Reads were processed and aligned using the

10X CellRanger multi pipeline to GRCh38 gex and vdj reference genomes (10X

Genomics). Each sample feature barcode matrix was loaded into R and analyzed

utilizing the Seurat package for gene expression, vdj and antibody capture analysis[119].

Cell processing was conducted as previously described[100]. Data are available at NCBI

GEO accession number GSE242775.

ELISpot Assay

Cryopreserved PBMC (5×10^6/sample) were thawed in prewarmed RPMI-1640 media

supplemented with L-glutamine + 10% FCS and 300ug DNAse. Thawed PBMCs were

rested overnight at 37 °C in X-VIVO™-15 Medium (Lonza) supplemented with 5%

human-AB serum. Cells were stimulated with ~1 nmol of peptide pool corresponding to

spike of Omicron (B.1.1.529) variant (16-mer peptide pools, overlapping by 10 amino

acids (21st century Biochemicals Inc.) on pre-coated human IFN-γ ELISpot plates

(Mabtech, Inc.) and developed after 18 hours according to manufacturer instructions.

Spots were imaged and counted using Iris FLUOROspot reader (Mabtech).

Statistical methods

All analyses are listed in the figure legends and were performed in GraphPad Prism 9

and/or the R programming language (v4.0.5).

Footnotes

[†] See 45 C.F.R. part 46; 21 C.F.R. part 56

[††] This study was reviewed by CDC and approved by the institutional review boards at

participating sites or under a reliance agreement with Abt Associates institutional review

board and was conducted consistent with applicable federal law and CDC policy under

45 C.F.R. part 46, 21 C.F.R. part 56, 42 U.S.C. Sect. 241(d), 5 U.S.C. Sect. 552a, 44

U.S.C. Sect. 3501 et seq.

References

1.   Novel 2019 coronavirus genome (2020). Virological. https://virological.org/t/novel-

2019-coronavirus-genome/319.

2.   Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D.,

Spector, S.A., Rouphael, N., Creech, C.B., et al. (2021). Efficacy and safety of the

mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. *384*, 403–416.

10.1056/NEJMoa2035389.

3.   Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.,

Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. *383*, 2603–

2615. 10.1056/NEJMoa2034577.

4.   Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B.,

Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021). Safety and

efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med.

384, 2187–2201. 10.1056/NEJMoa2101544.

5.   Tanriover, M.D., Doğanay, H.L., Akova, M., Güner, H.R., Azap, A., Akhan, S., Köse,

Ş., Erdinç, F.Ş., Akalın, E.H., Tabak, Ö.F., et al. (2021). Efficacy and safety of an

inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a

double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet *398*,

213–222. 10.1016/S0140-6736(21)01429-X.

6. Heath, P.T., Galiza, E.P., Baxter, D.N., Boffito, M., Browne, D., Burns, F.,

Chadwick, D.R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021). Safety and

efficacy of NVX-CoV2373 covid-19 vaccine. N. Engl. J. Med. *385*, 1172–1183.

10.1056/NEJMoa2107659.

7. Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K.,

Angus, B., Baillie, V.L., Barnabas, S.L., Bhorat, Q.E., et al. (2021). Safety and

efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an

interim analysis of four randomised controlled trials in Brazil, South Africa, and the

UK. Lancet *397*, 99–111. 10.1016/S0140-6736(20)32661-1.

8. Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G.F., Tan, W., Wu, G., Xu,

M., Lou, Z., et al. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2

vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2

trial. Lancet Infect. Dis. *21*, 39–51. 10.1016/S1473-3099(20)30831-8.

9. Pouwels, K.B., Pritchard, E., Matthews, P.C., Stoesser, N., Eyre, D.W., Vihta, K.-D.,

House, T., Hay, J., Bell, J.I., Newton, J.N., et al. (2021). Effect of Delta variant on

viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the

UK. Nat. Med. *27*, 2127–2135. 10.1038/s41591-021-01548-7.

10. Chen, J., Wang, R., Gilby, N.B., and Wei, G.-W. (2022). Omicron variant

(B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inf.

Model. *62*, 412–422. 10.1021/acs.jcim.1c01451.

11. Tao, K., Tzou, P.L., Nouhin, J., Gupta, R.K., de Oliveira, T., Kosakovsky Pond, S.L.,

Fera, D., and Shafer, R.W. (2021). The biological and clinical significance of

emerging SARS-CoV-2 variants. Nat. Rev. Genet., 1–17. 10.1038/s41576-021-

00408-x.

12. Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn,

H.M.E., Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., et al. (2022). SARS-CoV-2

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody

responses. Cell. 10.1016/j.cell.2021.12.046.

13. Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W.,

Zhou, H., Houchens, C.R., Martins, K., Jayashankar, L., et al. (2022). Immune

correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

Science *375*, 43–50. 10.1126/science.abm3425.

14. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A.,

Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing

antibody levels are highly predictive of immune protection from symptomatic SARS-

CoV-2 infection. Nat. Med. *27*, 1205–1211. 10.1038/s41591-021-01377-8.

15. Rausch, J.W., Capoferri, A.A., Katusiime, M.G., Patro, S.C., and Kearney, M.F.

(2020). Low genetic diversity may be an Achilles heel of SARS-CoV-2. Proc. Natl.

Acad. Sci. U. S. A. *117*, 24614–24616. 10.1073/pnas.2017726117.

16. Volz, E. (2023). Fitness, growth and transmissibility of SARS-CoV-2 genetic

variants. Nat. Rev. Genet., 1–11. 10.1038/s41576-023-00610-z.

17. Wiegand, T., Nemudryi, A., Nemudraia, A., McVey, A., Little, A., Taylor, D.N., Walk,

S.T., and Wiedenheft, B. (2022). The Rise and Fall of SARS-CoV-2 Variants and

Ongoing Diversification of Omicron. Viruses *14*, 2009. 10.3390/v14092009.

18. Hill, V., Du Plessis, L., Peacock, T.P., Aggarwal, D., Colquhoun, R., Carabelli, A.M.,

Ellaby, N., Gallagher, E., Groves, N., Jackson, B., et al. (2022). The origins and

molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. *8*,

veac080. 10.1093/ve/veac080.

19. Cao, Y., Song, W., Wang, L., Liu, P., Yue, C., Jian, F., Yu, Y., Yisimayi, A., Wang,

P., Wang, Y., et al. (2022). Characterization of the enhanced infectivity and

antibody evasion of Omicron BA.2.75. Cell Host Microbe *30*, 1527-1539.e5.

10.1016/j.chom.2022.09.018.

20. Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley,

W.R., Laydon, D.J., Dabrera, G., O'Toole, Á., et al. (2021). Assessing

transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature *593*, 266–269.

10.1038/s41586-021-03470-x.

21. Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P.,

Singh, S., Abraham, P., Panda, S., et al. (2021). Convergent evolution of SARS-

CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-

19 in Maharashtra, India. bioRxiv, 2021.04.22.440932. 10.1101/2021.04.22.440932.

22. Cheng, Y.-W., Chao, T.-L., Li, C.-L., Wang, S.-H., Kao, H.-C., Tsai, Y.-M., Wang,

H.-Y., Hsieh, C.-L., Lin, Y.-Y., Chen, P.-J., et al. (2021). D614G Substitution of

SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via

Enhanced Furin-Mediated Spike Cleavage. MBio, e0058721. 10.1128/mBio.00587-

21.

23. McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A.C., Di Iulio, J., Tortorici,

M.A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021). SARS-CoV-2

immune evasion by the B.1.427/B.1.429 variant of concern. Science.

10.1126/science.abi7994.

24. Imai, M., Halfmann, P.J., Yamayoshi, S., Iwatsuki-Horimoto, K., Chiba, S.,

Watanabe, T., Nakajima, N., Ito, M., Kuroda, M., Kiso, M., et al. (2021).

Characterization of a new SARS-CoV-2 variant that emerged in Brazil. PNAS.

10.1073/pnas.2106535118/-/DCSupplemental.

25. Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L.,

Anyaneji, U.J., Bester, P.A., Boni, M.F., Chand, M., et al. (2022). Rapid epidemic

expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature *603*,

679–686. 10.1038/s41586-022-04411-y.

26. Sokal, A., Chappert, P., Barba-Spaeth, G., Roeser, A., Fourati, S., Azzaoui, I.,

Vandenberghe, A., Fernandez, I., Meola, A., Bouvier-Alias, M., et al. (2021).

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell

184, 1201-1213.e14. 10.1016/j.cell.2021.01.050.

27. Muecksch, F., Weisblum, Y., Barnes, C.O., Schmidt, F., Schaefer-Babajew, D.,

Wang, Z., C Lorenzi, J.C., Flyak, A.I., DeLaitsch, A.T., Huey-Tubman, K.E., et al.

(2021). Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency,

breadth, and resilience to viral escape mutations. Immunity.

10.1016/j.immuni.2021.07.008.

28. Turner, J.S., O'Halloran, J.A., Kalaidina, E., Kim, W., Schmitz, A.J., Zhou, J.Q., Lei,

T., Thapa, M., Chen, R.E., Case, J.B., et al. (2021). SARS-CoV-2 mRNA vaccines

induce persistent human germinal centre responses. Nature. 10.1038/s41586-021-

03738-2.

29. Kim, W., Zhou, J.Q., Horvath, S.C., Schmitz, A.J., Sturtz, A.J., Lei, T., Liu, Z.,

Kalaidina, E., Thapa, M., Alsoussi, W.B., et al. (2022). Germinal centre-driven

maturation of B cell response to mRNA vaccination. Nature, 1–8. 10.1038/s41586-

022-04527-1.

30. Victora, G.D., and Nussenzweig, M.C. (2022). Germinal centers. Annu. Rev.

Immunol. *40*, 413–442. 10.1146/annurev-immunol-120419-022408.

31. Seifert, M., Przekopowitz, M., Taudien, S., Lollies, A., Ronge, V., Drees, B.,

Lindemann, M., Hillen, U., Engler, H., Singer, B.B., et al. (2015). Functional

capacities of human IgM memory B cells in early inflammatory responses and

secondary germinal center reactions. Proc. Natl. Acad. Sci. U. S. A. *112*, E546-55.

10.1073/pnas.1416276112.

32. Dogan, I., Bertocci, B., Vilmont, V., Delbos, F., Mégret, J., Storck, S., Reynaud, C.-

A., and Weill, J.-C. (2009). Multiple layers of B cell memory with different effector

functions. Nat. Immunol. *10*, 1292–1299. 10.1038/ni.1814.

33. Pape, K.A., Taylor, J.J., Maul, R.W., Gearhart, P.J., and Jenkins, M.K. (2011).

Different B cell populations mediate early and late memory during an endogenous

immune response. Science *331*, 1203–1207. 10.1126/science.1201730.

34. Zuccarino-Catania, G.V., Sadanand, S., Weisel, F.J., Tomayko, M.M., Meng, H.,

Kleinstein, S.H., Good-Jacobson, K.L., and Shlomchik, M.J. (2014). CD80 and PD-

L2 define functionally distinct memory B cell subsets that are independent of

antibody isotype. Nat. Immunol. *15*, 631–637. 10.1038/ni.2914.

35. Horikawa, K., Martin, S.W., Pogue, S.L., Silver, K., Peng, K., Takatsu, K., and

Goodnow, C.C. (2007). Enhancement and suppression of signaling by the

conserved tail of IgG memory-type B cell antigen receptors. J. Exp. Med. *204*, 759–

769. 10.1084/jem.20061923.

36. Waisman, A., Kraus, M., Seagal, J., Ghosh, S., Melamed, D., Song, J., Sasaki, Y.,

Classen, S., Lutz, C., Brombacher, F., et al. (2007). IgG1 B cell receptor signaling is

inhibited by CD22 and promotes the development of B cells whose survival is less

dependent on Ig alpha/beta. J. Exp. Med. *204*, 747–758. 10.1084/jem.20062024.

37. Engels, N., König, L.M., Heemann, C., Lutz, J., Tsubata, T., Griep, S., Schrader, V.,

and Wienands, J. (2009). Recruitment of the cytoplasmic adaptor Grb2 to surface

IgG and IgE provides antigen receptor-intrinsic costimulation to class-switched B

cells. Nat. Immunol. *10*, 1018–1025. 10.1038/ni.1764.

38. Kometani, K., Nakagawa, R., Shinnakasu, R., Kaji, T., Rybouchkin, A., Moriyama,

S., Furukawa, K., Koseki, H., Takemori, T., and Kurosaki, T. (2013). Repression of

the transcription factor Bach2 contributes to predisposition of IgG1 memory B cells

toward plasma cell differentiation. Immunity *39*, 136–147.

10.1016/j.immuni.2013.06.011.

39. Bhattacharya, D., Cheah, M.T., Franco, C.B., Hosen, N., Pin, C.L., Sha, W.C., and

Weissman, I.L. (2007). Transcriptional profiling of antigen-dependent murine B cell

differentiation and memory formation. J. Immunol. *179*, 6808–6819.

10.4049/jimmunol.179.10.6808.

40. Tomayko, M.M., Anderson, S.M., Brayton, C.E., Sadanand, S., Steinel, N.C.,

Behrens, T.W., and Shlomchik, M.J. (2008). Systematic comparison of gene

expression between murine memory and naive B cells demonstrates that memory B

cells have unique signaling capabilities. J. Immunol. *181*, 27–38.

10.4049/jimmunol.181.1.27.

41. Wong, R., Belk, J.A., Govero, J., Uhrlaub, J.L., Reinartz, D., Zhao, H., Errico, J.M.,

D'Souza, L., Ripperger, T.J., Nikolich-Zugich, J., et al. (2020). Affinity-Restricted

Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses.

Immunity *53*, 1078-1094.e7. 10.1016/j.immuni.2020.09.001.

42. Mesin, L., Schiepers, A., Ersching, J., Barbulescu, A., Cavazzoni, C.B., Angelini, A.,

Okada, T., Kurosaki, T., and Victora, G.D. (2020). Restricted clonality and limited

germinal center reentry characterize memory B cell reactivation by boosting. Cell

180, 92-106.e11. 10.1016/j.cell.2019.11.032.

43. Purtha, W.E., Tedder, T.F., Johnson, S., Bhattacharya, D., and Diamond, M.S.

(2011). Memory B cells, but not long-lived plasma cells, possess antigen

specificities for viral escape mutants. J. Exp. Med. *208*, 2599–2606.

10.1084/jem.20110740.

44. Francis, T. (1960). On the Doctrine of Original Antigenic Sin. Proc. Am. Philos. Soc.

104, 572–578.

45. Worobey, M., Plotkin, S., and Hensley, S.E. (2020). Influenza Vaccines Delivered in

Early Childhood Could Turn Antigenic Sin into Antigenic Blessings. Cold Spring

Harb. Perspect. Med. *10*. 10.1101/cshperspect.a038471.

46. Anderson, E.M., Li, S.H., Awofolaju, M., Eilola, T., Goodwin, E., Bolton, M.J.,

Gouma, S., Manzoni, T.B., Hicks, P., Goel, R.R., et al. (2022). SARS-CoV-2

infections elicit higher levels of original antigenic sin antibodies compared with

SARS-CoV-2 mRNA vaccinations. Cell Rep. *41*, 111496.

10.1016/j.celrep.2022.111496.

47. Amanat, F., Thapa, M., Lei, T., Sayed Ahmed, S.M., Adelsberg, D.C., Carreno,

J.M., Strohmeier, S., Schmitz, A.J., Zafar, S., Zhou, J.Q., et al. (2021). SARS-CoV-

2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2.

Cell. 10.1016/j.cell.2021.06.005.

48. Worobey, M., Han, G.-Z., and Rambaut, A. (2014). Genesis and pathogenesis of

the 1918 pandemic H1N1 influenza A virus. Proc. Natl. Acad. Sci. U. S. A. *111*,

8107–8112. 10.1073/pnas.1324197111.

49. Taubenberger, J.K., and Morens, D.M. (2006). 1918 Influenza: the mother of all

pandemics. Emerg. Infect. Dis. *12*, 15–22. 10.3201/eid1201.050979.

50. Gostic, K.M., Bridge, R., Brady, S., Viboud, C., Worobey, M., and Lloyd-Smith, J.O.

(2019). Childhood immune imprinting to influenza A shapes birth year-specific risk

during seasonal H1N1 and H3N2 epidemics. PLoS Pathog. *15*, e1008109.

10.1371/journal.ppat.1008109.

51. Gostic, K.M., Ambrose, M., Worobey, M., and Lloyd-Smith, J.O. (2016). Potent

protection against H5N1 and H7N9 influenza via childhood hemagglutinin

imprinting. Science *354*, 722–726. 10.1126/science.aag1322.

52. Greaney, A.J., Eguia, R.T., Starr, T.N., Khan, K., Franko, N., Logue, J.K., Lord,

S.M., Speake, C., Chu, H.Y., Sigal, A., et al. (2022). The SARS-CoV-2 Delta variant

induces an antibody response largely focused on class 1 and 2 antibody epitopes.

PLoS Pathog. *18*, e1010592. 10.1371/journal.ppat.1010592.

53. Abbott, R.K., Lee, J.H., Menis, S., Skog, P., Rossi, M., Ota, T., Kulp, D.W., Bhullar,

D., Kalyuzhniy, O., Havenar-Daughton, C., et al. (2018). Precursor Frequency and

Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with

Germline-Targeting HIV Vaccine Immunogens. Immunity *48*, 133-146.e6.

10.1016/j.immuni.2017.11.023.

54. Chan, T.D., Gatto, D., Wood, K., Camidge, T., Basten, A., and Brink, R. (2009).

Antigen affinity controls rapid T-dependent antibody production by driving the

expansion rather than the differentiation or extrafollicular migration of early

plasmablasts. J. Immunol. *183*, 3139–3149. 10.4049/jimmunol.0901690.

55. Anderson, S.M., Khalil, A., Uduman, M., Hershberg, U., Louzoun, Y., Haberman,

A.M., Kleinstein, S.H., and Shlomchik, M.J. (2009). Taking advantage: high-affinity

B cells in the germinal center have lower death rates, but similar rates of division,

compared to low-affinity cells. J. Immunol. *183*, 7314–7325.

10.4049/jimmunol.0902452.

56. Shih, T.-A.Y., Meffre, E., Roederer, M., and Nussenzweig, M.C. (2002). Role of

BCR affinity in T cell dependent antibody responses in vivo. Nat. Immunol. *3*, 570–

575. 10.1038/ni803.

57. Yeh, C.-H., Nojima, T., Kuraoka, M., and Kelsoe, G. (2018). Germinal center entry

not selection of B cells is controlled by peptide-MHCII complex density. Nat.

Commun. *9*, 1–11. 10.1038/s41467-018-03382-x.

58. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., and Hendrickson,

W.A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the

CD4 receptor and a neutralizing human antibody. Nature *393*, 648–659.

10.1038/31405.

59. Grant, O.C., Montgomery, D., Ito, K., and Woods, R.J. (2020). Analysis of the

SARS-CoV-2 spike protein glycan shield reveals implications for immune

recognition. Sci. Rep. *10*, 14991. 10.1038/s41598-020-71748-7.

60. Chan, T.D., Wood, K., Hermes, J.R., Butt, D., Jolly, C.J., Basten, A., and Brink, R.

(2012). Elimination of germinal-center-derived self-reactive B cells is governed by

the location and concentration of self-antigen. Immunity *37*, 893–904.

10.1016/j.immuni.2012.07.017.

61. Reed, J.H., Jackson, J., Christ, D., and Goodnow, C.C. (2016). Clonal redemption

of autoantibodies by somatic hypermutation away from self-reactivity during human

immunization. J. Exp. Med. *213*, 1255–1265. 10.1084/jem.20151978.

62. Sabouri, Z., Schofield, P., Horikawa, K., Spierings, E., Kipling, D., Randall, K.L.,

Langley, D., Roome, B., Vazquez-Lombardi, R., Rouet, R., et al. (2014).

Redemption of autoantibodies on anergic B cells by variable-region glycosylation

and mutation away from self-reactivity. Proc. Natl. Acad. Sci. U. S. A. *111*, E2567-

75. 10.1073/pnas.1406974111.

63. Sangesland, M., Torrents de la Peña, A., Boyoglu-Barnum, S., Ronsard, L.,

Mohamed, F.A.N., Moreno, T.B., Barnes, R.M., Rohrer, D., Lonberg, N.,

Ghebremichael, M., et al. (2022). Allelic polymorphism controls autoreactivity and

vaccine elicitation of human broadly neutralizing antibodies against influenza virus.

Immunity *55*, 1693-1709.e8. 10.1016/j.immuni.2022.07.006.

64. Berman, J.E., Nickerson, K.G., Pollock, R.R., Barth, J.E., Schuurman, R.K.,

Knowles, D.M., Chess, L., and Alt, F.W. (1991). VH gene usage in humans: biased

usage of the VH6 gene in immature B lymphoid cells. Eur. J. Immunol. *21*, 1311–

1314. 10.1002/eji.1830210532.

65. Willems van Dijk, K., Milner, L.A., Sasso, E.H., and Milner, E.C. (1992).

Chromosomal organization of the heavy chain variable region gene segments

comprising the human fetal antibody repertoire. Proc. Natl. Acad. Sci. U. S. A. *89*,

10430–10434. 10.1073/pnas.89.21.10430.

66. Nadel, B., Tang, A., Lugo, G., Love, V., Escuro, G., and Feeney, A.J. (1998).

Decreased frequency of rearrangement due to the synergistic effect of nucleotide

changes in the heptamer and nonamer of the recombination signal sequence of the

V kappa gene A2b, which is associated with increased susceptibility of Navajos to

Haemophilus influenzae type b disease. J. Immunol. *161*, 6068–6073.

67. Murray, S.M., Ansari, A.M., Frater, J., Klenerman, P., Dunachie, S., Barnes, E., and

Ogbe, A. (2023). The impact of pre-existing cross-reactive immunity on SARS-CoV-

2 infection and vaccine responses. Nat. Rev. Immunol. *23*, 304–316.

10.1038/s41577-022-00809-x.

68. Chemaitelly, H., Ayoub, H.H., Tang, P., Hasan, M.R., Coyle, P., Yassine, H.M., Al-

Khatib, H.A., Smatti, M.K., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022). Immune

Imprinting and Protection against Repeat Reinfection with SARS-CoV-2. N. Engl. J.

Med. 10.1056/NEJMc2211055.

69. Koutsakos, M., and Ellebedy, A.H. (2023). Immunological imprinting: Understanding

COVID-19. Immunity *56*, 909–913. 10.1016/j.immuni.2023.04.012.

70. Alsoussi, W.B., Malladi, S.K., Zhou, J.Q., Liu, Z., Ying, B., Kim, W., Schmitz, A.J.,

Lei, T., Horvath, S.C., Sturtz, A.J., et al. (2023). SARS-CoV-2 Omicron boosting

induces de novo B cell response in humans. Nature *617*, 592–598.

10.1038/s41586-023-06025-4.

71. Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li,

Q., Chen, X., et al. (2022). BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by

Omicron infection. Nature *608*, 593–602. 10.1038/s41586-022-04980-y.

72. Cao, Y., Jian, F., Wang, J., Yu, Y., Song, W., Yisimayi, A., Wang, J., An, R., Chen,

X., Zhang, N., et al. (2023). Imprinted SARS-CoV-2 humoral immunity induces

convergent Omicron RBD evolution. Nature *614*, 521–529. 10.1038/s41586-022-

05644-7.

73. Park, Y.-J., Pinto, D., Walls, A.C., Liu, Z., De Marco, A., Benigni, F., Zatta, F.,

Silacci-Fregni, C., Bassi, J., Sprouse, K.R., et al. (2022). Imprinted antibody

responses against SARS-CoV-2 Omicron sublineages. Science *378*, 619–627.

10.1126/science.adc9127.

74. Reynolds, C.J., Gibbons, J.M., Pade, C., Lin, K.-M., Sandoval, D.M., Pieper, F.,

Butler, D.K., Liu, S., Otter, A.D., Joy, G., et al. (2022). Heterologous infection and

vaccination shapes immunity against SARS-CoV-2 variants. Science *375*, 183–192.

10.1126/science.abm0811.

75. Gagne, M., Moliva, J.I., Foulds, K.E., Andrew, S.F., Flynn, B.J., Werner, A.P.,

Wagner, D.A., Teng, I.-T., Lin, B.C., Moore, C., et al. (2022). mRNA-1273 or

mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion,

951  neutralizing responses, and protection from Omicron. Cell *185*, 1556-1571.e18.

952  10.1016/j.cell.2022.03.038.

953 76. Masurel, N. (1969). RELATION BETWEEN HONG KONG VIRUS AND FORMER

954  HUMAN A2 ISOLATES AND THE A/EQUI2 VIRUS IN HUMAN SERA COLLECTED

955  BEFORE 1957. Lancet *293*, 907–910. 10.1016/S0140-6736(69)92544-6.

956 77. Masurel, N., and Heijtink, R.A. (1983). Recycling of H1N1 influenza A virus in man--

957  a haemagglutinin antibody study. J. Hyg. *90*, 397–402.

958  10.1017/s0022172400029028.

959 78. Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Gálvez, R.I.,

960  Cortes, F.H., Grifoni, A., Tarke, A., Chang, J., et al. (2022). Humoral and cellular

961  immune memory to four COVID-19 vaccines. Cell *185*, 2434-2451.e17.

962  10.1016/j.cell.2022.05.022.

963 79. Kaplonek, P., Fischinger, S., Cizmeci, D., Bartsch, Y.C., Kang, J., Burke, J.S., Shin,

964  S.A., Dayal, D., Martin, P., Mann, C., et al. (2022). mRNA-1273 vaccine-induced

965  antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern.

966  Immunity. 10.1016/j.immuni.2022.01.001.

967 80. Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O.,

968  Gouma, S., Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021). Distinct antibody

969  and memory B cell responses in SARS-CoV-2 naïve and recovered individuals

970  following mRNA vaccination. Sci Immunol *6*. 10.1126/sciimmunol.abi6950.

81. Greaney, A.J., Loes, A.N., Gentles, L.E., Crawford, K.H.D., Starr, T.N., Malone,

K.D., Chu, H.Y., and Bloom, J.D. (2021). Antibodies elicited by mRNA-1273

vaccination bind more broadly to the receptor binding domain than do those from

SARS-CoV-2 infection. Science Translational Medicine.

10.1126/scitranslmed.abi9915.

82. Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P.,

Singh, S., Abraham, P., Panda, S., et al. (2021). SARS-CoV-2 spike mutations,

L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in

Maharashtra, India. Microorganisms *9*, 1542. 10.3390/microorganisms9071542.

83. Akinbami, L.J., Kruszon-Moran, D., Wang, C.-Y., Storandt, R.J., Clark, J., Riddles,

M.K., and Mohadjer, L.K. (2022). SARS-CoV-2 serology and self-reported infection

among adults - National Health and Nutrition Examination Survey, United States,

august 2021-may 2022. MMWR Morb. Mortal. Wkly. Rep. *71*, 1522–1525.

10.15585/mmwr.mm7148a4.

84. Jones, J.M., Manrique, I.M., Stone, M.S., Grebe, E., Saa, P., Germanio, C.D.,

Spencer, B.R., Notari, E., Bravo, M., Lanteri, M.C., et al. (2023). Estimates of

SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections

among blood donors, by COVID-19 vaccination status - United States, April 2021-

September 2022. MMWR Morb. Mortal. Wkly. Rep. *72*, 601–605.

10.15585/mmwr.mm7222a3.

85. Lutrick, K., Ellingson, K.D., Baccam, Z., Rivers, P., Beitel, S., Parker, J., Hollister,

J., Sun, X., Gerald, J.K., Komatsu, K., et al. (2021). COVID-19 infection, reinfection,

and vaccine effectiveness in a prospective cohort of Arizona frontline/essential

workers: The AZ HEROES research protocol. JMIR Res. Protoc. *10*, e28925.

10.2196/28925.

86. Edwards, L.J., Fowlkes, A.L., Wesley, M.G., Kuntz, J.L., Odean, M.J., Caban-

Martinez, A.J., Dunnigan, K., Phillips, A.L., Grant, L., Herring, M.K., et al. (2021).

"Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel

(RECOVER) Study: Protocol for a multi-site longitudinal cohort." JMIR Res Protoc

7.

87. Rambaut, A., Holmes, E.C., O'Toole, Á., Hill, V., McCrone, J.T., Ruis, C., du

Plessis, L., and Pybus, O.G. (2020). A dynamic nomenclature proposal for SARS-

CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. *5*, 1403–1407.

10.1038/s41564-020-0770-5.

88. Ripperger, T.J., Uhrlaub, J.L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato,

H.A., Thompson, M.R., Bradshaw, C., Weinkauf, C.C., Bime, C., et al. (2020).

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-

Prevalence Communities and Reveal Durable Humoral Immunity. Immunity *53*,

925-933.e4. 10.1016/j.immuni.2020.10.004.

89. Piccoli, L., Park, Y.-J., Tortorici, M.A., Czudnochowski, N., Walls, A.C., Beltramello,

M., Silacci-Fregni, C., Pinto, D., Rosen, L.E., Bowen, J.E., et al. (2020). Mapping

Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-

Binding Domain by Structure-Guided High-Resolution Serology. Cell *183*, 1024-

1042.e21. 10.1016/j.cell.2020.09.037.

90. Greaney, A.J., Loes, A.N., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y.,

and Bloom, J.D. (2021). Comprehensive mapping of mutations in the SARS-CoV-2

receptor-binding domain that affect recognition by polyclonal human plasma

antibodies. Cell Host Microbe *29*, 463-476.e6. 10.1016/j.chom.2021.02.003.

91. Röltgen, K., Nielsen, S.C.A., Silva, O., Younes, S.F., Zaslavsky, M., Costales, C.,

Yang, F., Wirz, O.F., Solis, D., Hoh, R.A., et al. (2022). Immune imprinting, breadth

of variant recognition, and germinal center response in human SARS-CoV-2

infection and vaccination. Cell *185*, 1025-1040.e14. 10.1016/j.cell.2022.01.018.

92. Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L.A., Binshtein, E., Zost,

S.J., Nargi, R.S., Sutton, R.E., Winkler, E.S., Chen, E.C., et al. (2021). Neutralizing

and protective human monoclonal antibodies recognizing the N-terminal domain of

the SARS-CoV-2 spike protein. Cell *184*, 2316-2331.e15.

10.1016/j.cell.2021.03.029.

93. Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E.R., Yu, J.,

Bahna, F., Bimela, J., et al. (2021). Potent SARS-CoV-2 neutralizing antibodies

directed against spike N-terminal domain target a single supersite. Cell Host

Microbe *29*, 819-833.e7. 10.1016/j.chom.2021.03.005.

94. McCallum, M., De Marco, A., Lempp, F.A., Tortorici, M.A., Pinto, D., Walls, A.C.,

Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021). N-terminal domain

antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell *184*, 2332-

2347.e16. 10.1016/j.cell.2021.03.028.

95. Shroff, R.T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M.V.,

Peyton, K.L., Uhrlaub, J.L., Ripperger, T.J., Jergović, M., et al. (2021). Immune

responses to two and three doses of the BNT162b2 mRNA vaccine in adults with

solid tumors. Nat. Med., 1–10. 10.1038/s41591-021-01542-z.

96. Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T.S., Ngare, I.,

Kimura, I., Uriu, K., Kosugi, Y., et al. (2021). SARS-CoV-2 spike L452R variant

evades cellular immunity and increases infectivity. Cell Host Microbe.

10.1016/j.chom.2021.06.006.

97. He, P., Liu, B., Gao, X., Yan, Q., Pei, R., Sun, J., Chen, Q., Hou, R., Li, Z., Zhang,

Y., et al. (2022). SARS-CoV-2 Delta and Omicron variants evade population

antibody response by mutations in a single spike epitope. Nat Microbiol.

10.1038/s41564-022-01235-4.

98. Tchesnokova, V., Kulasekara, H., Larson, L., Bowers, V., Rechkina, E., Kisiela, D.,

Sledneva, Y., Choudhury, D., Maslova, I., Deng, K., et al. (2021). Acquisition of the

L452R mutation in the ACE2-binding interface of spike protein triggers recent

massive expansion of SARS-CoV-2 variants. J. Clin. Microbiol. *59*, e0092121.

10.1128/JCM.00921-21.

99. Greaney, A.J., Starr, T.N., Eguia, R.T., Loes, A.N., Khan, K., Karim, F., Cele, S.,

Bowen, J.E., Logue, J.K., Corti, D., et al. (2022). A SARS-CoV-2 variant elicits an

antibody response with a shifted immunodominance hierarchy. PLoS Pathog. *18*,

e1010248. 10.1371/journal.ppat.1010248.

100.   Setliff, I., Shiakolas, A.R., Pilewski, K.A., Murji, A.A., Mapengo, R.E., Janowska,

K., Richardson, S., Oosthuysen, C., Raju, N., Ronsard, L., et al. (2019). High-

Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell *179*,

1636-1646.e15. 10.1016/j.cell.2019.11.003.

101.   Schiepers, A., van 't Wout, M.F.L., Greaney, A.J., Zang, T., Muramatsu, H., Lin,

P.J.C., Tam, Y.K., Mesin, L., Starr, T.N., Bieniasz, P.D., et al. (2023). Molecular

fate-mapping of serum antibody responses to repeat immunization. Nature.

10.1038/s41586-023-05715-3.

102.   Smith, K.G., Light, A., Nossal, G.J., and Tarlinton, D.M. (1997). The extent of

affinity maturation differs between the memory and antibody-forming cell

compartments in the primary immune response. EMBO J. *16*, 2996–3006.

10.1093/emboj/16.11.2996.

103.   Lavinder, J.J., Wine, Y., Giesecke, C., Ippolito, G.C., Horton, A.P., Lungu, O.I.,

Hoi, K.H., DeKosky, B.J., Murrin, E.M., Wirth, M.M., et al. (2014). Identification and

characterization of the constituent human serum antibodies elicited by vaccination.

Proc. Natl. Acad. Sci. U. S. A. *111*, 2259–2264. 10.1073/pnas.1317793111.

104.   Pape, K.A., Maul, R.W., Dileepan, T., Paustian, A.S., Gearhart, P.J., and

Jenkins, M.K. (2018). Naive B cells with high-avidity germline-encoded antigen

receptors produce persistent IgM+ and transient IgG+ memory B cells. Immunity *48*,

1135-1143.e4. 10.1016/j.immuni.2018.04.019.

105.   Andrews, S.F., Kaur, K., Pauli, N.T., Huang, M., Huang, Y., and Wilson, P.C.

1078   (2015). High preexisting serological antibody levels correlate with diversification of

1079   the influenza vaccine response. J. Virol. *89*, 3308–3317. 10.1128/JVI.02871-14.

1080   106.   Inoue, T., Shinnakasu, R., Kawai, C., Yamamoto, H., Sakakibara, S., Ono, C.,

1081   Itoh, Y., Terooatea, T., Yamashita, K., Okamoto, T., et al. (2023). Antibody

1082   feedback contributes to facilitating the development of Omicron-reactive memory B

1083   cells in SARS-CoV-2 mRNA vaccinees. J. Exp. Med. *220*. 10.1084/jem.20221786.

1084   107.   Liu, Y.J., Zhang, J., Lane, P.J., Chan, E.Y., and MacLennan, I.C. (1991). Sites of

1085   specific B cell activation in primary and secondary responses to T cell-dependent

1086   and T cell-independent antigens. Eur. J. Immunol. *21*, 2951–2962.

1087   10.1002/eji.1830211209.

1088   108.   Abbott, R.K., and Crotty, S. (2020). Factors in B cell competition and

1089   immunodominance. Immunol. Rev. *296*, 120–131. 10.1111/imr.12861.

1090   109.   Krammer, F. (2019). The human antibody response to influenza A virus infection

1091   and vaccination. Nat. Rev. Immunol. *19*, 383–397. 10.1038/s41577-019-0143-6.

1092   110.   Chia, P.Y., Ong, S.W.X., Chiew, C.J., Ang, L.W., Chavatte, J.-M., Mak, T.-M.,

1093   Cui, L., Kalimuddin, S., Chia, W.N., Tan, C.W., et al. (2022). Virological and

1094   serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a

1095   multicentre cohort study. Clin. Microbiol. Infect. *28*, 612.e1-612.e7.

1096   10.1016/j.cmi.2021.11.010.

111.   Schaefer-Babajew, D., Wang, Z., Muecksch, F., Cho, A., Loewe, M., Cipolla, M.,

Raspe, R., Johnson, B., Canis, M., DaSilva, J., et al. (2023). Antibody feedback

regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature *613*, 735–

742. 10.1038/s41586-022-05609-w.

112.   Gao, Y., Cai, C., Grifoni, A., Müller, T.R., Niessl, J., Olofsson, A., Humbert, M.,

Hansson, L., Österborg, A., Bergman, P., et al. (2022). Ancestral SARS-CoV-2-

specific T cells cross-recognize the Omicron variant. Nat. Med. *28*, 472–476.

10.1038/s41591-022-01700-x.

113.   Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan,

K., Cele, S., Bernstein, M., Karim, F., et al. (2022). T cell responses to SARS-CoV-2

spike cross-recognize Omicron. Nature *603*, 488–492. 10.1038/s41586-022-04460-

3.

114.   Bartsch, Y.C., Wang, C., Zohar, T., Fischinger, S., Atyeo, C., Burke, J.S., Kang,

J., Edlow, A.G., Fasano, A., Baden, L.R., et al. (2021). Humoral signatures of

protective and pathological SARS-CoV-2 infection in children. Nat. Med. *27*, 454–

462. 10.1038/s41591-021-01263-3.

115.   Ying, B., Scheaffer, S.M., Whitener, B., Liang, C.-Y., Dmytrenko, O., Mackin, S.,

Wu, K., Lee, D., Avena, L.E., Chong, Z., et al. (2022). Boosting with Omicron-

matched or historical mRNA vaccines increases neutralizing antibody responses

and protection against B.1.1.529 infection in mice. bioRxivorg, 2022.02.07.479419.

10.1101/2022.02.07.479419.

116.   Barnes, C.O., West, A.P., Jr, Huey-Tubman, K.E., Hoffmann, M.A.G., Sharaf,

N.G., Hoffman, P.R., Koranda, N., Gristick, H.B., Gaebler, C., Muecksch, F., et al.

(2020). Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal

Common Epitopes and Recurrent Features of Antibodies. Cell *182*, 828-842.e16.

10.1016/j.cell.2020.06.025.

117.   Hay, J.A., Kissler, S.M., Fauver, J.R., Mack, C., Tai, C.G., Samant, R.M.,

Connolly, S., Anderson, D.J., Khullar, G., MacKay, M., et al. (2022). Quantifying the

impact of immune history and variant on SARS-CoV-2 viral kinetics and infection

rebound: A retrospective cohort study. Elife *11*. 10.7554/eLife.81849.

118.   Goldfarb, D.M., Tilley, P., Al-Rawahi, G.N., Srigley, J.A., Ford, G., Pedersen, H.,

Pabbi, A., Hannam-Clark, S., Charles, M., Dittrick, M., et al. (2020). Self-collected

saline gargle samples as an alternative to healthcare worker collected

nasopharyngeal swabs for COVID-19 diagnosis in outpatients. J. Clin. Microbiol.,

2020.09.13.20188334. 10.1101/2020.09.13.20188334.

119.   Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A.,

Lee, M.J., Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of

multimodal single-cell data. Cell *184*, 3573-3587.e29. 10.1016/j.cell.2021.04.048.

A.

B.

Figure 1. Primary and recall antibody responses to Wuhan and Delta strains of

SARS-COV-2. (A) Virus neutralization assays were performed using the WA-1 and

Delta isolates of SARS-CoV-2. Serial 1:3 dilutions of serums were performed and tested

for the ability to prevent plaque formation on Vero cells. The lowest concentration

capable of preventing more than 90% of plaques was considered to be the $PRNT_{90}$

value. Each symbol represents an individual. Two-sided P values from t-test statistics

were calculated for pairwise differences using two-way ANOVA. Post hoc testing for

multiple comparisons between draws was performed using Tukey's multiple

comparisons test. P values greater than 0.05 are not depicted. (**B)** Quantitative titers of

WuHu1- and Delta RBD-specific antibodies. Serum was initially diluted 1:60, serially

diluted 1:3, assessed by ELISA for binding to the listed antigens, and area under the

curve (AUC) values were calculated. Each symbol represents an individual. WuHu1

AUC values were divided by their Delta AUC titer in the same individual to calculate a

WuHu1:Delta RBD ratio in the rightmost panel. Two-sided P values from t-test statistics

were calculated for pairwise differences using one-way ANOVA. Post hoc testing for

multiple comparisons between draws was performed using Tukey's multiple

comparisons test. P values greater than 0.05 are not depicted.

A.

B.

C.

Figure 2. WuHu1 and Delta Memory B cell flow cytometric analysis and

quantification. (A) Representative flow cytometric plots of Wuhu1 and Delta S1-

specific memory B cells (full gating strategy shown in Figure S2) in naïve, primary Delta

infection, and post-vaccination Delta infection cohorts. Cells that bind both WuHu1 S1

and Delta S1 are annotated as cross-reactive S1+, whereas cells that bind only WuHu1

S1 or Delta S1 are annotated as WuHu1 S1+ or Delta S1+, respectively. **(B)**

Quantification of isotype-switched memory B cells as a percentage of total PBMCs for

Wuhu1 S1+, Delta S1+ and cross-reactive S1+ specificities for each cohort of SARS-

CoV-2 immune histories. Each symbol represents an individual. Two-sided P values

from t-test statistics were calculated for pairwise differences using one-way ANOVA.

Post hoc testing for multiple comparisons between draws was performed using Tukey's

multiple comparisons test. P values greater than 0.05 are not depicted. **(C)** Correlation

of post-infection cross-reactive S1 MBCs (calculated as in Figure 2B) plotted against the

frequency of post-infection Delta S1-specific MBCs (calculated as in Figure 2B) in

individuals that experienced a post-vaccination Delta infection. Pearson correlation

analysis was performed.

1170

1171

Figure 3

A.

B.

C.

D.

Figure 3. Epitope-specific quantification of Delta RBD- and Delta NTD-specific

antibodies and memory B cells. (**A**) A chimeric protein (Delta RBD-L452) was

generated in which R452 was reverted to the ancestral L452. ELISAs were used to

quantify serum antibodies that bound to Delta RBD-L452 in each cohort. Delta RBD-

L452 AUC titers were divided by Delta RBD titers (Figure 1B) in the same individuals to

calculate a L452:R452 titer ratio. Each symbol represents an individual. Two-sided P

values from t-test statistics were calculated for pairwise differences using one-way

ANOVA. Post hoc testing for multiple comparisons between draws was performed using

Tukey's multiple comparisons test. P values greater than 0.05 are not depicted. (**B**) A

chimeric protein (Delta NTD-WuHu1 S1) was generated in which Delta NTD mutated

epitopes (T19R, G142D, E156-, F157-, R158G) were incorporated into the otherwise

WuHu1 S1 backbone. ELISAs were used to quantify serum antibodies that bound to

Delta NTD-WuHu1 S1 in each cohort. Delta RBD-L452 AUC titers were divided by their

Delta RBD (Supplemental Fig 1A) titer to calculate a WuHu1 NTD:Delta NTD titer ratio.

Each symbol represents an individual. Two-sided P values from t-test statistics were

calculated for pairwise differences using one-way ANOVA. Post hoc testing for multiple

comparisons between draws was performed using Tukey's multiple comparisons test. P

values greater than 0.05 are not depicted. (**C**) LIBRA-seq plots of isotype-switched

memory B cells enriched for Spike-binding specificities from primary Delta infections.

Read count thresholds to determine positivity were set using samples in which cells

lacking Spike-binding specificities were sorted and sequenced. Plots are concatenated

from ten individuals. (**D**) Quantification of Delta RBD-specific and Delta NTD-specific

memory B cells (MBCs) in individuals that experienced a primary Delta infection. Lines

connect specificities within the same individual. Delta RBD-specific cells were classified

by cells that had Delta RBD read counts of greater than 160 and WuHu1 S1 read

counts of less than 35. Delta NTD-specific cells were classified by cells that had Delta

NTD-WuHu1 S1 read counts of greater than 23 and WuHu1 S1 read counts of less than

35. Two-sided P values were calculated for pairwise differences using paired t-tests.

1200

1201

1202

1203

1204

A.

B.

Figure 4. Primary and recall antibody responses to Wuhan and BA.1 strains of

SARS-COV-2. (A) Virus neutralization assays were performed using the WA-1 and

BA.1 isolates of SARS-CoV-2. Serial 1:3 dilutions of serums were performed and tested

for the ability to prevent plaque formation on Vero cells. The lowest concentration

capable of preventing more than 90% of plaques was considered to the $PRNT_{90}$ value.

Each symbol represents an individual. Two-sided P values from t-test statistics were

calculated for pairwise differences using two-way ANOVA. Post hoc testing for multiple

comparisons between draws was performed using Tukey's multiple comparisons test. P

values greater than 0.05 are not depicted. **(B)** Quantitative titers of Wuhu1 and BA.1

RBD antibodies. Serum was initially diluted 1:60, serially diluted 1:3, assessed by

ELISA for binding to the listed antigens, and area under the curve (AUC) values were

calculated. Each symbol represents an individual. WuHu1 AUC values were divided by

their BA.1 RBD AUC titer in the same individual to calculate a ratio in the rightmost

panel. Two-sided P values from t-test statistics were calculated for pairwise differences

using one-way ANOVA. Post hoc testing for multiple comparisons between draws was

performed using Tukey's multiple comparisons test. P values greater than 0.05 are not

depicted.

1222

1223

A.

B.

C.

D.

Figure 5. WuHu1 and BA.1 Memory B cell flow cytometric analysis and

quantification. (A) Representative flow cytometric plots of Wuhu1 and BA.1 RBD-

specific memory B cells (full gating strategy shown in Figure S3) in naïve, vaccinated

only, primary BA.1 infection, and post-vaccination BA.1 infection cohorts. Cells that bind

both WuHu1 RBD and BA.1 RBD are annotated as cross-reactive RBD+, whereas cells

that bind only WuHu1 RBD or BA.1 RBD are annotated as WuHu1 RBD+ or BA.1

RBD+, respectively. **(B)** Quantification of isotype-switched memory B cells for Wuhu1

RBD+, BA.1 RBD+ and cross-reactive RBD+ specificities for each cohort of SARS-CoV-

2 immune histories. Each symbol represents an individual. Two-sided P values from t-

test statistics were calculated for pairwise differences using one-way ANOVA. Post hoc

testing for multiple comparisons between draws was performed using Tukey's multiple

comparisons test. P values greater than 0.05 are not depicted. **(C)** Representative flow

cytometric plots of Wuhu1 and BA.1 Spike-specific memory B cells (full gating strategy

shown in Figure S3) in naïve, vaccinated only, primary BA.1 infection, and post-

vaccination BA.1 infection cohorts. Cells that bind both WuHu1 RBD and BA.1 Spike

are annotated as cross-reactive Spike+, whereas cells that bind only WuHu1 Spike or

BA.1 Spike are annotated as WuHu1 Spike+ or BA.1 Spike+, respectively. **(D)**

Quantification of isotype-switched memory B cells for Wuhu1 Spike+, BA.1 Spike+ and

cross-reactive Spike+ specificities for each cohort of SARS-CoV-2 immune histories.

Each symbol represents an individual. Two-sided P values from t-test statistics were

calculated for pairwise differences using one-way ANOVA. Post hoc testing for multiple

comparisons between draws was performed using Tukey's multiple comparisons test. P

values greater than 0.05 are not depicted.

A.

B.

Figure 6. Frequency of WuHu1- and BA.1-specific memory B cells before and after

BA.1 infection. (A) Frequencies of isotype-switched memory B cells with Wuhu1

RBD+, BA.1 RBD+ and cross-reactive RBD+ specificities in both unvaccinated and

vaccinated individuals before and after BA.1 infection. Lines connect the same

individual from pre-infection frequency to post-infection frequency. In primary infections,

pre-infection blood draws were taken on average 75.6 days before infection and post-

infection blood draws occurred on 37.8 days after infection. In post-vaccination

infections, pre-infection blood draws were taken on average 87.6 days before infection

and post-infection draws were taken an average of 38.3 days after infection. Individuals

that received a vaccine after the pre-infection draw were excluded from analysis. P

values were calculated using Wilcoxon matched-pairs signed rank test on each row and

post hoc testing for multiple comparisons between draws was performed using two-

stage linear step-up procedure of Benjamini, Krieger and Yekutieli. P values greater

than 0.05 are not depicted. **(B)** Frequencies of isotype-switched memory B cells with

Wuhu1 Spike+, BA.1 Spike+ and cross-reactive Spike+ specificities in both

unvaccinated and vaccinated individuals before and after BA.1 infection. Lines connect

the same individual from pre-infection frequency to post-infection frequency. P values

were calculated using Wilcoxon matched-pairs signed rank test on each row and post

hoc testing for multiple comparisons between draws was performed using two-stage

linear step-up procedure of Benjamini, Krieger and Yekutieli. P values greater than 0.05

are not depicted.

1268

1269

A.

B.   **Figure 7**

C.

D.

Figure 7. Correlations of pre-infection and post-infection BA.1-specific antibody,

T and B cell responses. (A) Correlation of pre-infection cross-reactive Spike MBCs

(calculated as in Figure 5C) plotted against the frequency of post-infection BA.1 Spike

MBCs (calculated as in Figure 5C) in individuals that experienced a post-vaccination

BA.1 infection. Pearson correlation analysis was performed. Pre-infection blood draws

were taken on average 87.6 days before infection and post-infection draws were taken

an average of 38.3 days after infection. Individuals that received a vaccine after the pre-

infection draw were excluded from analysis. **(B)** Correlation of post-infection cross-

reactive Spike MBCs (calculated as in Figure 6B) plotted against the frequency of post-

infection BA.1 Spike MBCs (calculated as in Figure 5C) in individuals that experienced a

post-vaccination BA.1 infection. Pearson correlation analysis was performed. **(C)**

Correlation of pre-infection BA.1 neutralizing antibody titer (calculated as in Figure 4a)

plotted against post infection BA.1 Spike MBCs (calculated as in Figure 5c) in

individuals that experienced a post-vaccination BA.1 infection. Pearson correlation

analysis was performed. **(D)** Correlation of pre-infection BA.1 Spike-specific T cells as

measured by IFNγ ELISPOTs plotted against post-infection BA.1 Spike MBCs in

individuals that experienced a post-vaccination BA.1 infection. Pearson correlation

analysis was performed.

1288

1289

A.

B.

Figure S1. Test All, Test Smart (TATS) symptom report. (A) Percentage of

individuals from each TATS cohort that reported experiencing various respiratory/cold

symptoms in study entry survey. **(B)** Reported days until symptoms resolved for each

TATS cohort. Two-sided P values from t-test statistics were calculated for pairwise

differences using one-way ANOVA. Post hoc testing for multiple comparisons between

draws was performed using Tukey's multiple comparisons test. P values greater than

0.05 are not depicted.

1297

A.

Figure S2

TATS Delta cohort PANGO-lineages

27 B.1.617.2/B.1.617.2-like
12 Unassigned

Total=39

TATS BA.1 cohort PANGO-lineages

9 BA.1/BA.1-like
7 Unassigned

Total=16

B.

TATS PANGO-lineages during Delta recruitment period
(July 1, 2021-December 1, 2021)

198 B.1.617.2/B.1.617.2-like
144 Unassigned

Total=342

TATS PANGO-lineages during BA.1 recruitment period
(January 1, 2022 -March 31, 2022)

206 BA.1/BA.1-like
4 BA.2
4 Recombinant
5 B.1.617.2/B.1.617.2-like
2 A
30 Unassigned

Total=251

Figure S2. PANGO-lineage assignments from TATS PCR positive individuals. (A)

Delta or BA.1 PANGO-lineage assignments after SARS-CoV-2 viral amplicon

sequencing (Integrated DNA Technologies). Unassigned sequences could not be

assigned to a PANGO-lineage due to insufficient viral RNA recovery and low sequence

coverage. **(B)** PANGO-lineage assignments of all TATS samples submitted during the

period of Delta cohort recruitment, July 1, 2021-December 1, 2021 (left panel) or during

the period of BA.1 cohort recruitment, January 1, 2022-March 31, 2022 (right panel).

Unassigned sequences could not be assigned a lineage due to insufficient viral RNA

recovery and low sequence coverage.

Figure S3. Primary and recall antibody responses to Wuhan and Delta strains of

SARS-COV-2. Quantitative titers of WuHu1- and Delta S1-specific antibodies. Serum

was initially diluted 1:60, serially diluted 1:3, assessed by ELISA for binding to the listed

antigens, and area under the curve (AUC) values were calculated. Each symbol

represents an individual. WuHu1 AUC values were divided by their Delta AUC titer in

the same individual to calculate a WuHu1:Delta S1 ratio in the rightmost panel. Two-

sided P values from t-test statistics were calculated for pairwise differences using one-

way ANOVA. Post hoc testing for multiple comparisons between draws was performed

using Tukey's multiple comparisons test. P values greater than 0.05 are not depicted.

1316

1317

1318

1319

primary Delta

post-vaccination Delta

1320 **Figure S4. Flow cytometric gating strategy with Delta S1 and WuHu1 S1**

1321 **tetramers.** Examples of a sample from a primary Delta infection (top) and post-

1322 vaccination Delta infection (bottom) are shown.

1323

A.

B.

C.

Figures S5. LIBRA-seq analysis in primary and post-vaccination Delta infections

and quantification of somatic mutations. (A) A chimeric protein (Delta NTD-WuHu1

S1) was generated in which Delta NTD mutated epitopes (T19R, G142D, E156-, F157-,

R158G) were incorporated into the otherwise WuHu1 S1 backbone. Quantification of

Delta RBD-specific **(left)** and Delta NTD-specific memory B cells **(right)** in individuals

that experienced a post-vaccination Delta infection. Delta RBD-specific cells were

classified by cells that had Delta RBD read counts of greater than 300 and WuHu1 S1

read counts of less than 35. Delta NTD-specific cells were classified by cells that had

Delta NTD-WuHu1 S1 read counts of greater than 23 and WuHu1 S1 read counts of

less than 35. Read count thresholds to determine positivity were set using samples in

which cells lacking Spike-binding specificities were sorted and sequenced. Plots are

concatenated from ten individuals. **(B)** Somatic mutations were calculated using the

observedMutations command in the Shazam Immcantation package in R. Specificities

of cells are determined using the same cutoffs described in **Figure S3A and 3D. (C)**

Quantification of somatic mutations of all Spike specific cells subjected to scRNAseq

from either ten primary or post-vaccination Delta infections.

1340

1341

1342

1343

1344

α-Nucleocapsid 1:60 Titer

Figure S6

1345 **Figure S6. anti-Nucleocapsid titers in uninfected individuals.** Individuals with α-

1346 Nucleocapsid titers of greater than 0.6 at a1:60 serum dilution were considered

1347 previously infected and excluded from the study.

1348

1349

1350 **Figure S7. Flow cytometric gating strategy with BA.1 RBD, BA.1 Spike, WuHu1**

1351 **RBD and WuHu1 Spike tetramers.** An example of a sample from a post-vaccination

1352 BA.1 infection is shown.

1353

1354

A.

B.

Figure S8. **WuHu1 and BA.1 Memory B cell flow cytometric quantification. (A)**

Cells that bind both WuHu1 RBD and BA.1 RBD are annotated as cross-reactive RBD+,

whereas cells that bind only WuHu1 RBD or BA.1 RBD are annotated as WuHu1 RBD+

or BA.1 RBD+, respectively. Quantification of isotype-switched memory B cells as a

percentage of total PBMCs for Wuhu1 RBD+, BA.1 RBD+ and cross-reactive RBD+

specificities for each cohort of SARS-CoV-2 immune histories. Each symbol represents

an individual. Two-sided P values from t-test statistics were calculated for pairwise

differences using two-way ANOVA. Post hoc testing for multiple comparisons between

draws was performed using Tukey's multiple comparisons test. P values greater than

0.05 are not depicted. **(B)** Cells that bind both WuHu1 RBD and BA.1 Spike are

annotated as cross-reactive Spike+, whereas cells that bind only WuHu1 Spike or BA.1

Spike are annotated as WuHu1 Spike+ or BA.1 Spike+, respectively. Quantification of

isotype-switched memory B cells for Wuhu1 Spike+, BA.1 Spike+ and cross-reactive

Spike+ specificities for each cohort of SARS-CoV-2 immune histories. Each symbol

represents an individual. Two-sided P values from t-test statistics were calculated for

pairwise differences using two-way ANOVA. Post hoc testing for multiple comparisons

between draws was performed using Tukey's multiple comparisons test. P values

greater than 0.05 are not depicted.

1373

Table 1

	vaccinated only (statewide antibody testing initiative) (n=74)	primary Delta (n=12)	post-vaccination Delta (n=37)	vaccinated only (TATS) (n=62)	primary BA.1 (n=69)	post-vaccination BA.1 (n=62)
Age Mean (s.d.)	38.0 (32.0, 54.0)	21.9 (20.2, 40.7)	23.3 (18.6, 65.8)	31.9 (18.6, 65.0)	44 (25, 62)	40 (19, 71.5)
Sex						
Male	22 (32%)	5 (42%)	8 (22%)	24 (39%)		24 (39%)
Female	52 (68%)	7 (58%)	29 (78%)	37 (60%)		34 (55%)
Prior COVID infection						
Yes		12 (100%)	37 (100%)		69 (100%)	64 (100%)
No	74 (100%)					
Time since COVID infection		67.5 days (32, 99.3)	71.5 days (48.5, 89.5)		40 days (31, 44.5)	54.4 days (34.5, 71)
paired pre- and post- infection samples					10	21
Time from vaccination to pre- infection draw						138 (32.5, 217)
Time from pre- infection draw to infection					73.3 days (30, 99)	112 days (33, 187)
Time from infection to post- infection draw					42.7 days (29.5, 47.5)	44.8 days (34, 49.3)
COVID Vaccination # of shots	37	0	37	62	0	62
2	37 (100%)		37 (100%)	16 (26%)		13 (20%)
3				46 (74%)		15 (23%)
4						3 (5%)
time since vaccination	135.6 days (126, 270)		273.9 days (56, 317)	176.0 days (113.5, 188)		192.2 days (107, 302.3)

1374 **Table 1. Characteristics of cohorts**

1375 Interquartile range (IQR) is listed in parentheses unless otherwise stated in the table.

1376